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CHAPTER 1 INTRODUCTION

1.1 HIV epidemiology
According to the report of the Joint United Nations Program on HIV/AIDS
(UNAIDS), about 2.6 million people became infected with AIDS in 2009 and an
estimated 33.3 million people were living with the disease by the end of the year (1).
Though the number of new infections and AIDS-related deaths have been steadily
decreasing over the past few years (1), AIDS is still a serious global public health
problem and a heavy socioeconomic burden.

Figure 1.1 HIV life cycle. Adapted based on the figure produced by Pomerantz RJ and
Horn DL (2).

2

1.2 HIV Life cycle
The human immunodeficiency virus (HIV) infects CD4 positive T cells through the
interaction between viral envelope glycoprotein (gp120 and gp41) and CD4 receptor as
well as co-receptors (CCR5 or CXCR4). After the virus anchors to the CD4 positive T
cell, the HIV virion fuses with the target cell. The nucleocapsid containing the viral
genome, viral proteins, and reverse transcriptase are released to the cytoplasm of the
target cell. The viral genome encodes three essential enzymes, the reverse transcriptase,
integrase, and protease. The first viral encoded enzyme, reverse transcriptase,
reverse-transcribes viral RNA to DNA. As reverse transcriptase degrades the RNA
template, a complementary DNA strand is synthesized to form a double stranded duplex
called proviral DNA. Integrase then inserts the proviral DNA into the host genome. The
inserted proviral DNA is first transcribed into a messenger RNA and then translated into a
polyprotein. At this step, the third viral enzyme, the HIV protease, is required to cleave
the polyprotein into eight separate proteins and two small spacer peptides. The mature
viral structural proteins assemble around the viral genome into new functional viruses. As
the new viron buds from its host cell membrane, it is coated with viral envelope proteins
and departs to begin a new infectious cycle.

1.3 The HIV-1 genome
The HIV genome consists of a long single stranded RNA molecule. The viral
genome contains three main open reading frames, the group-specific antigen gene (gag),
the polymerase gene (pol), and the envelope gene (env). The gag gene encodes the p55
precursor polyprotein which is processed to generate the matrix protein (MA, p17), capsid
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protein (CA, p24), nucleocapsid protein (NC, p7), spacer peptide 1 (SP1, p2), spacer
peptide 2 (SP2, p1), and p6. The pol gene encodes three viral enzymes, which are the
reverse transcriptase, integrase, and protease. The reading frames of gag and pol differ by
one nucleotide. During translation, ribosomal frame-shifting produces the Gag-Pol
polyprotein. The frequency of this frame-shifting is about 5 to 10% (3). Therefore, the
three viral enzymes are expressed in the Gag-Pol precursor. The env gene encodes a
precursor, gp160, which is processed by the host protease to generate the external
glycoprotein gp120 and the transmembrane glycoprotein gp41. The Tat protein encoded
by the transactivator gene (tat) is an essential viral regulatory factor interacting with an
RNA element to activate transcription. Another essential regulatory factor is coded by the
regulator of virion gene (rev), which promotes the nuclear export of the viral RNA. The
product of virion infectivity factor gene (vif) preserves viral infectivity by inducing the
degradation of an antiretroviral cytidine deaminase, APOBEC3G (apoplipoprotein B
mRNA-editing, enzyme-catalytic, polypeptide-like 3G) (4). The viral protein R encoded
by vpr gene regulates nuclear import of the HIV-1 pre-integration complex (5), arrests
cell growth (6), and induces host cell apoptosis (7). The viral protein U gene (vpu) only
exists in HIV-1. Its gene product induces CD4 degradation in the endoplasmic reticulum
and enhances virion release from HIV-1-infected cells (8). The negative regulator protein
gene (nef) encodes a multifunctional protein, which actually has a positive role in
maintaining high viral load (9). The long terminal repeats (LTRs) are located at each end
of the HIV-1 genome.
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Figure 1.2 The HIV-1 genome. Open reading frames are shown as rectangles.

1.4 The HIV-1 protease
In the HIV life cycle, the protease is an essential element for viral maturation. The
HIV protease is a homodimeric aspartyl protease, and each monomer is composed of 99
amino acid residues with a catalytic aspartate at position 25. HIV-1 protease cleaves Gag
and Gag-Pol polyprotein precursor encoded by the HIV-1 virus genome at nine
processing sites to produce mature active proteins. The Pol polyproteins is first cleaved
off from the Gag-Pol polyproteins and then further digested into protease, reverse
transcriptase (p51), RNase H (p15), and integrase. The active site is not fully exposed,
being covered by a two flexible β-hairpin flaps. The flaps need to open to allow the
substrates to access the active site. The HIV-1 protease enzyme activity can be inhibited
by blocking the active site of the protease.
Flaps

80s loop

80s loop

Active site
Asp25 Asp125

Dimerization domain

Figure 1.3 Structure of HIV-1 protease.
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1.5 Anti-HIV drugs
Since HIV was discovered in 1983 (10), 26 anti-HIV compounds were approved by
the U.S. FDA within almost three decades. The latest HIV drug, rilpivirine from Johnson
& Johnson Pharmaceuticals, was approved in May 2011. Anti-HIV drugs have been
developed to target the various steps in the HIV life cycle. Based on the targeted step of
HIV life cycle, anti-HIV drugs can be classified into five different categories: fusion
inhibitors, entry inhibitors, transcriptase inhibitors, integrase inhibitors, and protease
inhibitors. The cell entry inhibitors, enfuvirtide and maraviroc, block the entry of the viral
particle into the host CD4+ lymphocytes. Enfuvirtide interacts with the glycoprotein gp41
on the viral membrane to prevent the fusion of the viral particle and the host cell
membrane (11). Maraviroc is an antagonist of the CCR5 co-receptor, which only acts on
the macrophage-tropic (R5) HIV-1 strains (12). The inhibition of reverse transcriptase
stops the production of proviral DNA. There are two classes of reverse transcriptase
inhibitors, (i) Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTI) and (ii)
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI). In the case of NRTIs, both
nucleotide analog reverse-transcriptase inhibitors, such as tenofovir and adefovir, and
nucleoside analog reverse-transcriptase inhibitors, such as zidovudine (AZT), didanosine
(ddI), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), abacavir (ABC),
emtricitabine (FTC), entecavir (INN), and apricitabine (ATC), get incorporated into the
elongating DNA copy of HIV viral genome and cause premature termination of reverse
transcription. The NNRTIs, such as efavirenz, nevirapine, delavirdine, etravirine, and
rilpivirine bind to pockets other than the active site of reverse transcriptase and cause an
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allosteric effect that inhibits reverse transcription. Integrase inhibitors are the newest class
of antiretroviral agents. Raltegravir is the first integrase inhibitor approved by the U.S.
FDA. Elvitegravir is undergoing Phase 3 clinical trials. Both compounds inhibit the strand
transfer activity of integrase and halt the process of viral DNA integration (13, 14). The
proteolytic cleavage of the polyprotein precursor is also a critical step for viral maturation.
The inhibition of HIV protease effectively blocks the viral life cycle. The HIV-1 protease
and its inhibitors are introduced in the following sections.

1.6 Current HIV-1 protease inhibitors
Based on the 2010 global report from UNAIDS, there are more than five million
people receiving antiretroviral therapy, and this number is 13-fold higher than the number
for 2004 (1). The combination therapy of HIV-1 protease inhibitors and reverse
transcriptase inhibitors referred to as Highly Active Antiretroviral Therapy (HAART) is
the current AIDS therapy that is most effective. The AIDS-related mortality has dropped
sharply, and AIDS has gradually become a controllable, chronic disease. However, the
extended length of time that patients take the medication and the error-prone replication
of HIV genomes facilitate the evolution of drug resistant strains, which are the greatest
obstacle in the treatment of HIV-1/AIDS patients. Only a few mutations in HIV-1
protease are needed to confer drug resistance. There have been numerous studies
published regarding multi-drug resistance with a focus on HIV-1 protease (15).
The indispensable role of HIV-1 proteases in viral maturation makes it a popular
target for drug design. The numerous structures of HIV-1 protease have facilitated the
design of new and improved inhibitors. There are nine HIV-1 protease inhibitors

7

approved by the U.S. Food and Drug Administration (FDA); those inhibitors include:
saquinavir, indinavir, ritonavir, nelfinavir, amprenavir, lopinavir, atazanavir, tipranavir,
and darunavir. Unfortunately, resistance has been observed during the treatment with all
of the approved HIV-1 protease inhibitors, and resistance cannot be overcome by
increasing drug concentration due to the toxicity of protease inhibitors. Consequently,
resistance has caused protease inhibitor treatment failure in a great number of patients
(16). In the following section, the FDA-approved HIV-1 protease inhibitors are
introduced. There are structural similarities among those inhibitors, and they share a
similar binding pattern that might be the cause of the cross resistance characteristic of
HIV-1 protease inhibitors.

tipranavir

darunavir

amprenavir

lopinavir

atazanavir

saquinavir

indinavir

ritonavir

nelfinavir

Figure 1.4 Chemical structures of the HIV-1 protease inhibitors approved by the US
Food and Drug Administration.
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1.6.1 Saquinavir
Saquinavir (brand name: Invirase), the first FDA-approved HIV-1 protease inhibitor,
was invented by Hoffmann-La Roche Inc. The original design for the precursor of
saquinavir comprised a proline at the P1’ site and a phenylalanine at the P1 site. The
rationale is that HIV-1 protease cleaves the substrate between a phenylalanine and a
proline while mammalian proteases do not cleave substrates containing proline at the P1’
site. In the final structure of saquinavir, the proline was replaced by a
(S,S,S)-decahydro-isoquinoline- 3-carbonyl (DIQ) group to enhance the inhibitory
potency (Figure 1.2). The carbonyl of the DIQ group contacts the bridging water
molecule that interacts with the inhibitor and the flaps of HIV-1 protease (17).

1.6.2 Ritonavir
Ritonavir (brand name: Norvir), invented by Abbott Laboratories, was originally
designed as an HIV-1 protease inhibitor, but it was found later that ritonavir boosts the
circulating concentration of other HIV-1 protease inhibitors by inhibiting the cytochrome
P450 (18). Due to this function of ritonavir, it is still used with the second generation of
HIV-1 protease inhibitors. Boosted HIV-1 protease inhibitors elevate the drug resistance
barrier. With the isopropyl thiazolyl P3 group, ritonavir is longer than other
FDA-approved HIV-1 protease inhibitors (Figure 1.2).

1.6.3 Lopinavir
Lopinavir (brand name: Kaletra, containing lopinavir and ritonavir), from Abbott
Laboratories, was developed on the basis of ritonavir. The core region of lopinavir, a
hydroxyethylene dipeptide isostere, is the same as that of ritonavir (Figure 1.2). The P2
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and P2’ group are altered in lopinavir relative to ritonavir. The 5-thiazolyl P2 group of
ritonavir is changed to a phenoxyacetyl group, and the 2-isopropylthiazolyl P2’ group of
ritonavir is replaced by a six-member cyclic urea. In general, the new P2 and P2’ groups
are smaller, which is designed to decrease the contact with highly variable residues at the
82 site of HIV-1 protease (19). The substitution of the P2 and P2’ groups improves the
inhibitory potency of lopinavir against the drug-resistant variants of HIV-1 protease (19).

1.6.4 Indinavir
Indinavir (brand name: Crixivan) was developed by Merck & Co., Inc. An advantage
of indinavir is that it effectively inhibits both HIV-1 and HIV-2 while the disadvantage is
that the circulating indinavir concentration decreases quickly. The low plasma
concentration of indinavir usually leads to treatment failures (20). In addition, indinavir
has a low sulibility that may result in the patients developing kidney stones. For this
reason, indinavir has been replaced by second generation protease inhibitors.

1.6.5 Nelfinavir
Nelfinavir (brand name: Viracept) was made by Agouron Pharmaceuticals. One end
of the nelfinavir molecule has the same DIQ group as saquinavir (Figure 1.2). The other
end of nelfinavir contains a 2-methyl-3-hydroxybenzamide group. Another novel aspect
of the nelfinavir design is that the S-phenyl group at the P1 site magnifies the potency of
this inhibitor.

1.6.6 Amprenavir
Amprenavir (brand name: Agenerase), developed by Vertex Pharmaceuticals, has a
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benzyl group at the P1 site and an isobutyl group at the P1’ site (Figure 1.2). The P1’
group and the phenyl amide P2’ group are connected by a sulfonamide. The asymmetry of
the P1 and P1’ groups may favor the internal pseudosymmetry of HIV-1 protease.
Amprenavir contains fewer chiral centers than previous HIV-1 protease inhibitors. This
improvement simplifies the chemical synthesis and increases the oral availability (21).

1.6.7 Tipranavir
Tipranavir (brand name: Aptivus) is the only non-peptidomimetic HIV-1 protease
inhibitor, which received approval from the FDA in 2005. Due to dissimilarities with
other HIV-1 protease inhibitors, tipranavir encounters a relatively different HIV-1
protease resistance profile (22, 23). An innovation in the tipranavir design is the
functional substitution of the bridging water molecule connecting the inhibitor and
protease flaps. The lactone oxygen atom of the dihydropyrone ring of tipranavir interacts
directly with the Ile 50 residues in the flap region of the HIV-1 protease. The direct
interaction stabilizes the protease-inhibitor complex. Though the structure of tipranavir is
different from previous inhibitors, its contact residues of HIV-1 protease share many
similarities with other HIV-1 protease inhibitors. Furthermore, the adverse effects of
tipranavir are considerable, with one of the worst being hemorrhage (24).

1.6.8 Atazanavir
Atazanavir (brand name: Reyataz), approved in 2003, is an aza-dipeptide analogue,
which exhibits potent anti-HIV activity. The 50% effective concentration (EC50) of
atazanavir in cell culture is 2.6 to 5.3 nM (25). A unique character of atazanavir is the
presence of a large phenylpyridyl P1 group that is asymmetric relative to its benzyl P1’
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group.

1.6.9 Darunavir
Darunavir, approved in 2006, is the latest HIV-1 protease inhibitor on the market.
The hydrogen bonds that darunavir forms with the backbone of the HIV-1 protease slow
down the development of drug resistance (26). The structure of darunavir is very similar
to that of amprenavir. The only difference is that the P2 group of darunavir is a
double-ringed bis-tetrahydrofuran that replaces the single-ringed tetrahydrofuran of
amprenavir. This change allows darunavir to have more hydrogen bonds with the Asp 29
residues of HIV-1 protease (27). Darunavir or atazanavir coadministrated with ritonavir is
a current first-line antiretroviral regimen (28).

1.6.10 The common mechanism of inhibitor binding
Most current HIV-1 protease inhibitors were designed to mimic the substrate
transition state. The hydroxyl group of the inhibitor interacts with the carboxyl group of
the active site residues, Asp 25 and Asp 25´, by hydrogen bonds. Moreover, the
inhibitor-contacting residues of HIV-1 protease are relatively conserved, such as Gly 27,
Asp 29, Asp 30, and Gly 48. Despite the fact that diverse chemical groups have been
incorporated in HIV-1 protease inhibitors, the conserved contact profile of the chemical
groups still makes the protease inhibitors vulnerable to prevent drug resistance.
Most inhibitor development efforts are to modify the available HIV-1 protease
inhibitors, which inevitably causes the new inhibitors to inherit structural similarity with
previous inhibitors. There have been many attempts to further modify current inhibitors;
some have succeeded, while others have not shown significant benefits. A series of
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compounds has been tested to optimize the P1 group of lopinavir, but none of them has
shown significant benefits over the original lopinavir (29). The successful examples of
modified inhibitors are darunavir and lopinavir, which were modified compounds of
amprenavir and ritonavir, respectively.

1.6.11 New design approaches for HIV-1 protease inhibitors
Resistance has been observed with all the current HIV-1 protease inhibitors due to
their structural similarities. Therefore, novel scaffolds of HIV-1 protease inhibitors are
considered to be the key to overcoming drug resistance. With the combination therapy of
structurally diverse HIV-1 protease inhibitors, HIV-1 protease is less likely to develop
resistance to the inhibitors in the combination group.
Designing inhibitors based on the substrate envelope of HIV-1 protease is a recent
strategy to develop HIV-1 protease inhibitors. A substrate envelope is the overlapping
volume occupied by multiple substrates. Based on this theory, a substrate-based HIV-1
protease inhibitor, RO1, has been designed and synthesized (30). The results
demonstrated that RO1 has 5 to 10 fold higher inhibitory efficacy than current HIV-1
protease inhibitors (30). Among the current FDA-approved HIV-1 protease inhibitors,
only tipranavir forms hydrogen bonds with the flap residues of the protease. Inhibitor
RO1 forms more hydrogen bonds with HIV-1 protease, which enhances the binding
energy and is also a step towards the diversity of binding patterns. However, the contact
residues of RO1 are still the old pattern, and no novel contact has been established. The
difficulty of complete alteration of the binding pattern might be due to the inhibitor
design concept of substrate mimics. To develop new scaffolds of HIV-1 protease
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inhibitors, it is necessary to adopt drug discovery strategies other than substrate mimics.
New scaffolds of HIV-1 protease inhibitors might be the key to overcoming drug
resistance. It is very risky to explore new structures of inhibitors. One reason is that the
new scaffolds are less likely to be superior to the well-established old scaffolds.
Mozenavir’s structure is highly dissimilar from other HIV-1 protease inhibitors, which
was developed based on the cyclic urea scaffold (31). However, the clinical studies
showed that mozenavir did not show significant advantages compared to other protease
inhibitors on the market, and Gilead Sciences, Inc. stopped the development of mozenavir
(32). The other reason is that new scaffolds with fewer study backgrounds may cause
severe adverse effects. The relatively different structure of tipranavir may be not only the
reason for generating altered drug-resistance profiles, but it is also the cause of the
unpredictable side effects, such as hemorrhage. Based on the above summary, the
non-peptidomimetic HIV-1 protease inhibitors seem to have a higher tendency to cause
adverse effects.
The discovery of new HIV-1 protease scaffolds may rely on high-throughput
screening techniques. By screening large chemical libraries with diverse compound
structures, the leads of new HIV protease inhibitor scaffolds could be found. After
extensive modifications and tests, the leads of new scaffolds might become the next
generation of HIV-1 protease inhibitors possessing novel chemical structures and
alternative binding patterns to HIV-1 protease. A set of HIV-1 protease inhibitors that bind
and function by various mechanisms can greatly decrease the probability for the protease
to simultaneously develop resistance to all inhibitors.
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1.7 Protein-ligand interactions
The flexibility of the protein is important in the affinity and specificity of ligand
binding as well as product release. Optimal interactions between the enzyme and the
substrate are formed through induced conformational changes (33). The major
interactions between the protein and the ligand are electrostatic interactions, hydrogen
bonding, hydrophobic interactions, and van der Waals interactions. An electrostatic
interaction is formed when oppositely charged groups interact at a distance less than 4 Å.
(34). The charged state of some amino acid residues determines the local electrostatic
potential of the protein, which is an important component of molecular recognition. The
hydrogen bonds are interactions between a partially electronegative atom and a hydrogen
atom covalently bound with another partially electronegative atom. Both the main chain
of a protein and the side chain of polar amino acid residues can serve as hydrogen bond
donors and acceptors. In contrast with hydrophilic interactions, such as electrostatic
interaction and hydrogen bonding, which are usually on the surface of a protein,
hydrophobic interactions assemble the core of a protein during folding. Van der Waals
interactions represent attractive or repulsive force between proximate atoms. Despite the
fact that van der Waals interactions are weak, the considerable number of van der Waals
interactions determines the important role of this interaction in macromolecules, such as
protein folding, protein-protein interactions, and protein-ligand interactions.

1.7.1 Substrate binding to the HIV-1 protease
Understanding substrate binding is an important step in drug design. Based on the
MA/CA substrate cleavage site (Ser-Gln-Asn-Tyr-Pro-Ile-Val), the P1’ Pro substitution
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with 20 different residues has been tested to identify the preferred P1’ residues of HIV-1
protease, and hydrophobic residues, such as Leu, Ile, Val, Phe, and Tyr, are favorable at
the P1’ site (35).
The substrate envelope represents the conserved volume occupied by the nine HIV-1
protease substrates. Designing inhibitors that fit into the overlapping volume of substrates
can avoid the contacts with mutation hotspots of the protease (36). Based on this theory,
the inhibitors designed to fit inside the consensus volume defined by the substrates
exhibited potent inhibition against HIV-1 protease and low levels of resistance to a panel
of drug-resistant HIV-1 protease variants (37).
The most widely accepted mechanism for the hydrolysis of HIV-1 protease
substrates is the general acid and base mechanism (38) (Figure 1.3). In the active site of
the HIV-1 protease, one aspartate residue is protonated while the other aspartate residue is
deprotonated (39). During cleavage, the protonated aspartate residue transfers the
hydrogen atom to the scissile carbonyl oxygen (40). A water molecule in the active site
attacks the carbonyl group of the scissile peptide bond of the substrate and the cleavage
site of the substrate forms a tetrahedral oxyanion intermediate (41).
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Figure 1.5 HIV-1 protease substrate cleavage mechanism.
The Gly-rich flaps of HIV-1 protease alter the conformation from an “open” form to
a “closed” form after ligand binding. NMR studies have demonstrated the flexibility of
the flap region of the HIV-1 protease (42). The flexibility of the flaps is considered to be
essential for substrate binding and product release. After the substrate is incorporated into
the protease actives site, substrate binding stabilizes the interactions between the flaps of
HIV-1 protease. A water molecule bridges the flap residue Ile50 and Ile50’ with hydrogen
bonds, and this water molecule is not involved in catalysis (40).

1.8 Summary of the HIV-1 protease structures in the dissertation
The HIV protease structures mentioned in the dissertation are listed in the following
table. The residues involved in crystal packing were identified using PDBePISA (Protein
Interfaces, Surfaces and Assemblies) server.
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Table 1.1 Summary of the HIV-1 protease structures
PDB

Space
Description

code
2HB4

Apo WT HIV-1 protease isolate
NL4-3

Group
P 41212

Apo MDR HIV-1 protease variants
2HB2

with mutations 24I, 46I, 53L, 63P,

P 41212

77I, and 82A
1HHP

2PC0

Apo WT HIV-1 protease isolate
BRU
Apo WT HIV-1 protease isolate
BH10

P 41212
P 41212

Apo MDR HIV-1 protease 769
1TW7

with mutations 10I, 36V, 46L, 54V,

P 41

62V, 63P, 71V, 82A, 84V, and 90M

2Q5K

WT HIV-1 protease in complex
with lopinavir

P 212121

Unit cell

Residues involved in crystal
packing

Length (Å)

Angle (°)

a=48.99 b=48.99

α=90 β=90

4, 6-7, 35, 37, 41-42, 44, 46, 49-57,

c=105.62

γ=90

61, 63, 71-73, 77-79, 81, 88, 91-94

a=49.67 b=49.67

α=90 β=90

4, 6-7, 35, 42, 50-57, 61, 71-73,

c=109.61

γ=90

77-79, 81, 88, 91-94

a=50.2 b=50.2

α=90 β=90

4, 6-7, 35, 37, 42, 49-57, 61, 63,

c=106.8

γ=90

71-73, 77-79, 81, 88, 91-94

a=46.42 b=46.42

α=90 β=90

4, 6-7, 39-41, 46, 48-55, 60-61, 63,

c=101.37

γ=90

71-74, 79, 81, 88, 91-94

a=45.04 b=45.04

α=90 β=90

4, 6-7, 34, 37-44, 48-61, 63, 71-74,

c=105.74

γ=90

77-81, 88, 91-94

a=51.34 b=58.04

α=90 β=90

c=61.13

γ=90

1-4, 6-7, 12-19, 34-46, 48-53,
54-55, 57-58, 59, 61-63, 65, 67-72,
77-81, 88, 91-94, 96, 98-99
1-2, 4, 6-7, 12, 14, 17-21, 34-46,

2O4P

WT HIV-1 protease in complex
with tipranavir

P 21212

a=58.61 b=86.26

α=90 β=90

48-49, 51-53, 55, 57-58, 61, 63, 65,

c=45.89

γ=90

67-68, 70-73, 79-83, 88, 91-92, 94,
99

3SPK

MDR HIV-1 protease 769 in
complex with tipranavir

P 61

a=63.12 b=63.12

α=90 β=90

c=83.54

γ=120

1-4, 6-8, 10, 12-14, 16-21, 34-35,
37-41, 43-48, 51-53, 58, 65, 67-68,
74, 79-81, 94, 96, 98
2, 4, 6-7, 12, 14, 17-20, 34-37,

3BVB

WT HIV-1 protease in complex
with darunavir

P 21212

a=58.26 b=85.91

α=90 β=90

40-46, 48-53, 55, 57-58, 61, 63, 65,

c=46.05

γ=90

67-68, 70-73, 79-83, 88, 91-92, 94,
96

3SO9

1A8K

N/A

1KJ7

N/A

MDR HIV-1 protease 769 in
complex with darunavir

WT HIV-1 protease in complex
with CA/p2 P1’F peptide

MDR HIV-1 protease 769 in
complex with CA/p2 P1’F peptide

WT HIV-1 protease in complex
with p2/NC peptide

MDR HIV-1 protease 769 in
complex with p2/NC peptide

P 212121

P 1121

P 212121

P 212121

P 212121

a=28.9 b=66.38

α=90 β=90

c=90.84

γ=90

a=59.6 b=52.2

α=90 β=90

c=61.7

γ=90

a=28.77 b=65.39

α=90 β=90

c=92.82

γ=90

a=51.51 b=59.43

α=90 β=90

c=61.74

γ=90

a=28.62 b=63.85

α=90 β=90

c=91.11

γ=90

1-2, 4, 6, 14-18, 21, 34-46, 48-58,
60-65, 70, 72, 77-82, 87, 92-94, 96,
98-99
2, 4, 6, 10-12, 14, 19, 21, 34-35,
41-46, 52-55, 57, 63, 65, 67-68,
70-72, 79-81, 92
1-2, 4, 6, 14-19, 21, 29, 34-37,
39-46, 49-58, 60-61, 63-65, 67-68,
70-72, 77-82, 87, 91-94, 96, 98-99
1-4, 6-7, 12-14, 17, 19, 34-35, 37,
41-46, 48-55, 61, 63, 65, 67-72,
77-81, 88, 91-94, 96
1-2, 4, 6, 14-17, 19, 21, 34-44,
46-58, 59-61, 63-65,

67-72, 74,

77-82, 87, 91-94, 96, 98-99
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1.9 Hepatitis C virus and treatment
The hepatitis C virus (HCV), a member of the Flaviviridae family, is a
single-stranded positive sense RNA virus. It is the major risk factor for liver cirrhosis and
hepatocellular caricinoma and the virus infects approximately 170 million people
worldwide, four million of which are in the United States (43, 44). The classic treatment
for HCV infection is a combination of pegylated interferon and ribavirin. Both antiviral
drugs function indirectly since neither of them targets a specific HCV protein or RNA.
The pegylated interferon and ribavirin combination treatment requires a weekly injection
for 24 or 48 weeks, yet only less than 50% patients achieve a sustained virological
response. Furthermore, there are a number of serious adverse effects associated with
interferon treatment, such as leucopenia, thrombocytopenia, neutropenia, depression,
fatigue, and "flu-like" symptoms, that makes withstanding the long treatment period
difficult for patients (45). Consequently, there is a need for safer and more effective drugs
for the treatment of HCV.

1.10 HCV life cycle
The HCV infection starts with the virus binding to the cell surface receptor. Several
putative receptor molecules have been proposed, such as the cluster of differentiation 81
(CD81) (46), scavenger receptor B type I (SR-BI) (47), dendritic cell-specific
intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN or CD209) (48),
liver/lymph node-specific intercellular adhesion molecule-3 (ICAM-3)-grabbing integrin
(L-SIGN or CD209L) (49), low-density lipoprotein receptor (LDL-R) (50), and
asialoglycoprotein receptor (ASGP-R) (51). Due to the narrow host specificity, HCV only
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infects humans and chimpanzees. Genetically humanized mice expressing human CD81
and occludin are able to establish HCV infection (52). L-SIGN molecules abundantly
expressed on liver sinusoidal endothelial cells play a crucial role in HCV tissue tropism
(49).

Figure 1.6 HCV life cycle. Adapted from the figure produced by Moradpour D, et al (53)
After attaching to a host receptor, the viral surface glycoproteins trigger
receptor-mediated endocytosis. By uncoating the capsid shell of the virion,
positive-strand genomic RNAs are released from the virus, and the RNAs are attached to
the endoplasmic reticulum. A complementary negative-strand RNA is synthesized based
on the viral RNA. The negative-strand RNA is then utilized as a template to produce
thousands of positive-strand viral RNA copies by the viral polymerase NS5B. The
positive-strand RNA is used for polyprotein translation. The internal ribosome entry site
(IRES) of HCV RNA regulates the assembly of translation initiation complexes by
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recruiting both cellular proteins and viral proteins (54). Then, a large precursor
polyprotein with approximately 3,000 amino acid residues is synthesized using the viral
genomic RNA. A total of ten proteins are produced by the cleavage of the polyprotein.
The structural proteins are released by host enzymes while the non-structural proteins are
cleaved off by the viral enzyme. The zinc-dependent NS2-3 autoprotease liberates the NS3

by self-cleavage. The efficient NS2-3 proteinase activity requires the last 130 residues of
NS2 and the first 180 amino acids of NS3 (55). The NS3 assembles with its cofactor
NS4A and performs self-cleavage at the NS3-NS4A junction to liberate NS4A. The
NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B junctions are cleaved by NS3/4A protease
(56). A host peptidase cleaves the E1-E2 junction. The envelope proteins, E1 and E2,
form a heterodimer after N-glycosylation (57).
The core proteins are self-assembled and bind the viral RNA to generate the
nucleocapsid. The glycoproteins E1 and E2 associated with the double lipid layers form
an envelope to cover the nucleocapsid. The newly formed viral particles are secreted from
the host cell to initiate a new infectious cycle.

Figure 1.7 The HCV genome. Adapted from the figure produced by Tan SL, et al.(58)

1.11 The HCV protease
The HCV protease emerges as a desirable drug target, because it is essential for viral
maturation. The single polyprotein encoded by the HCV genome is proteolytically
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processed by the HCV NS3/4A serine protease which is responsible for the cleavage at
four junctions of the HCV polyprotein including NS3/4A (self-cleavage), NS4A/4B,
NS4B/5A, and NS5A/5B (59-61).
The extensive functional studies of NS3/4A protease and the solved crystal structures
have improved our understanding of this protease. NS3 is a bifunctional enzyme; the
protease domain is located at the N-terminus and a helicase domain at the C-terminus.
The protease and helicase domains function independently (62, 63). NS4A, a 54-residue
peptide, is required as a co-factor to increase the activity of the NS3 protease (64, 65);
this may be due to the incorporation of NS4A into the β sheet at the N-terminus of the
NS3 protease with tight non-covalent bonds (66). Another possible function of NS4A is to
anchor NS3 to the membrane (67).

telaprevir

boceprevir

Figure 1.8 Chemical structures of HCV protease inhibitors.

1.12 The HCV protease inhibitor, telaprevir
Currently, two HCV protease inhibitors have been approved by the US FDA,
telaprevir (VX-950) and boceprevir. Telaprevir is an oral drug approved in May 2011
which is a potent inhibitor of the genotype 1 HCV protease. Telaprevir was developed by
Vertex Pharmaceuticals as a peptidomimetic inhibitor, which is derived from the
N-terminal product of the NS4B/5A. Telaprevir inhibits the NS3/4A protease by binding
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to the active site with its α-ketoamide moiety. The crystal structure of the NS3 protease
with the NS4A peptide or NS3/4A fusion from HCV genotypes 1a and 1b have been
solved (66, 68). The shallow substrate-binding groove of the protease increases the
difficulty of inhibitor binding, but α-ketoamide inhibitors exhibited an unusual binding
mechanism in the catalytic site of the protease. By optimization of α-ketoamide as a
serine trap group to covalently anchor inhibitors and to increase their affinity to the
protease, telaprevir, a potent, covalent, reversible, and selective inhibitor of HCV NS3/4A
protease, was developed (69). The covalent bond between telaprevir and the protease is
hydrolysable, which makes telaprevir a reversible inhibitor.
After a treatment with telaprevir for 2 to 3 days, the viral load in patients with
genotype 1 chronic hepatitis C was reduced by hundred to thousand folds (70). At the end
of a 14-day treatment with Telaprevir, up to a 10,000-fold reduction in HCV viral load
was observed, while in some patients the virus became undetectable (70). Telaprevir
dramatically shortened the duration of therapy, and fewer adverse effects were noted (70,
71). Therefore, with such a drug, the efficacy and tolerability of HCV treatment could be
greatly enhanced. Furthermore, telaprevir cured the genotype 1 hepatitis C patients who
had failed to achieve a sustained virological response with interferon-based therapy.
At least six major HCV genotypes have been identified with varied geographic
distributions. Each genotype is further divided into subtypes. Genotype 1a HCV is
prevalent in North and South America; genotype 1b, in Europe and Asia; genotype 3, in
Australia and South Asia; genotype 4, in Egypt, France and Central Africa. Genotype 2
exists in Japan, China, the United States, and Europe. Genotype 5 is observed in South
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Africa and Saudi Arabia. Genotype 6 is restricted to Hong Kong, Macau, and Vietnam.
The various HCV genotypes respond differently to treatments. For example, patients
infected with genotype 2 HCV showed better response to the interferon therapy relative to
the other genotypes (72). Although telaprevir has demonstrated strong antiviral activity in
patients with chronic genotype 1 HCV infection in the clinical trial, its efficacies with the
HCV genotypes 4, 5, and 6 have not been fully investigated. The sequence similarities
between NS3 protease of genotype 1 and NS3 protease of genotype 4, 5, and 6 vary
approximately 60% to 80%. Due to the relatively low sequence similarity between the
HCV genotype 1 protease and proteases from other HCV genotypes, the inhibitory
efficacies of non-genotype 1 proteases is likely affected. Enzyme assays demonstrate that
the potency of telaprevir against the HCV NS3/4A proteases of genotype 2 is similar as
that of telaprevir against the genotype 1 HCV proteases, but telaprevir exhibited reduced
activity against the genotype 3 HCV proteases (73). Interestingly, the protein sequence
similarities between the genotype 1 and genotype 2 proteases are less similar compared to
the protease sequences between genotypes 1 and 3. Therefore, structural information is
critical to explain the varied potency of telaprevir against non-genotype 1 HCV proteases.
A previous study showed the mutations V36A/G/L/M and T54A/S in NS3/4A protease
from HCV genotype 1 strain were associated with low to medium levels of telaprevir
resistance (74). The mutation V36L exists in genotype 4a, 4d, 5a, and 6f HCV protease
sequences. Thus, the comparison of telaprevir binding between the HCV genotype 1
protease and proteases from other genotypes will provide an insight of how to modify the
inhibitor to restore the enzyme inhibition.
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CHAPTER 2 METHODS

2.1 Synthesis of lopinavir analog
The synthesis of the lopinavir analog (Figure 2.1) was modified from the lopinavir
synthesis developed by Abbott Laboratories (75). The amount of reagents described in the
following sections was optimized for lopinavir analog synthesis.
BnCl,

CH3CN,

K2CO3

NaNH2

Isobutyl Mg Cl
THF

THF

H2O

1

4

3

2

THF, iPrOH

(1) MsOH, NaBH4
(2) TFA, NaBH4

Imidazole

Palladium/C

EtOAc, THF

H2
MeOH

7

5

6
SOCl2

SOCl2

NaHCO3

THF, DMF

EtOAc, DMF

EtOAc, H2O

Acid-3

Acid-5

8

Figure 2.1 Synthetic scheme for the lopinavir analog.

2.1.1 Synthesis of (L)-N,N-dibenzylphenylalanine benzyl ester (compound 2)
In a round flask, 15 g L-phenylalanine (compound 1) and 49.8 g K2CO3 were
dissolved in water, and 44 ml benzyl bromide was then added to the aqueous solution.
The solution in the flask was boiled overnight. The reaction was stopped by cooling down
the flask to room temperature. Ethyl acetate and water were used to extract the organic
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phase from the product mixture. The benzyl ester in the organic phase was further washed
with saturated sodium chloride solution. The organic phase was dried in vacuo to yield a
thick yellow oil. The product was purified by a silica gel column chromatography (ethyl
acetate:n-hexane = 1:4 v/v) to yield 7.1 g benzyl ester (compound 2, 18% yield).

2.1.2 Synthesis of (4S)-4-dibenzylamino-3-oxo-5-phenyl-pentanonitrile (compound 3)
7.1 g benzyl ester dissolved in 19 ml anhydrous tetrahydrofuran (THF) was cooled to
-45°C with an acetone solution mixed with dry ice. 4.26 g sodium amide was dissolved in
47 ml anhydrous THF in a separate flask and cooled to -45 °C. The air in both sealed
flasks was replaced by nitrogen. 6.14 ml acetonitrile was added to the sodium amide
solution and reacted for 30 min to generate an anion solution. The cold anion solution was
transferred to the benzyl ester solution by syringe. The mixture was stirred at -45 °C for 7
hr. The progress of the reaction was monitored by sampling and examination using thin
layer chromatography (TLC). The Rf is 0.55 (ethyl acetate:n-hexane = 1:3 v/v). The
reaction was quenched with 50 ml 25% (w/v) aqueous citric acid. The organic phase was
extracted, washed with saturated sodium chloride solution, and dried with magnesium
sulfate. The crude product was dissolved in boiling ethanol. As the solution was cooled
down resulting in 4.5 g white product (74% yield per reaction).

2.1.3 Grignard reaction
3.8 g of magnesium turnings were cut and weighted in a dry two-funnel flask that
was connected to a condensation tower. The reaction system was dried thoroughly by
heating and filled with argon. After cooling the reaction system with ice, 17.7 ml of
1-chloro-2-methyl propane was added to the flask. Iodine powder (10 mg) and a few
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drops of 1,2-dibromoethane were added to the solution mixture as an activating agent.
The reaction was stirred at room temperature for 30 min. The boiling of this solution
indicated the generation of the Grignard reagent, isobutyl magnesium chloride. In a
separate flask, 4.5 g of compound 3 was dissolved with anhydrous THF and transferred to
the flask containing Grignard reagent. The reaction mixture was stirred over night at room
temperature. The reaction was stopped by addition of 10% (w/v) citric acid. The product
in the organic phase was extracted and purified by silica gel column chromatography with
(ethyl acetate:n-hexane = 1:20 v/v, Rf 0.39), which yielded 2.5 g of enaminone
(compound 4, 47% yield).

2.1.4 Reduction reaction
A two-step reduction reaction generated the largest percentage of desired enantiomer.
1 g sodium borohydride in 54 ml anhydrous THF was cooled to 0°C before 4.3 ml
methansulfonic acid was slowly added to the suspension. The slow addition was to ensure
that the temperature of the suspension remained below 5°C. A solution of enaminone (2 g)
dissolved in THF and 5 ml isopropanol was added the previous suspension. The mixture
was stirred at 4°C for 28 hr. In the second step of reduction, 5 ml trifluoroacetic acid was
slowly added to 2 g sodium borohydride in 26 ml THF to ensure a temperature below
15°C. The suspension was stirred at room temperature for 4 hr. The reaction was
quenched with 3 N sodium hydroxide. By adding tert-butyl methyl ether, the organic
layer was separated and washed with 0.5 N sodium hydroxide, 20% (w/v) ammonium
chloride, and 6% (w/v) sodium chloride.
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2.1.5 Coupling of Acid-5
In a flask filled with nitrogen gas, 0.7 g Acid-5, purchased from Biofine International
Inc. (Vancouver, Canada), was dissolved in 9.7 ml THF and cooled to 4°C. 0.35 ml
thionyl chloride was added dropwise to the Acid-5. The mixture was stirred for 5.5 hr
until it became a thick slurry. The slurry was dried in vacuo, dissolved in heptane, and
further dried to thoroughly evaporate the residual thionyl chloride. The dried product,
acyl chloride, was dissolved in 3.45 ml dimethylformamide. 1.5 g of product 5 was added
to 0.96 ml ethyl acetate containing 0.72 g dissolved imidazole. The solution was rapidly
transferred to the acyl chloride and stirred for 1 hr at 0°C followed by overnight stirring at
30°C. The reaction was quenched with an aqueous hydrochloric acid solution by
adjusting the aqueous layer to pH 3. The aqueous layer contained unreacted Acid-5, and
the organic layer was extracted for further clean up. The crude product was loaded on a
silica column. The impurity was eluted with a mobile phase of 90% hexane, 10%
isopropyl alcohol, and 0.1% ammonium hydroxide. The product was eluted with 89%
dichloromethane, 10% methanol, and 1% ammonium hydroxide.

2.1.6 Deprotection and Acid-3 coupling
Two benzyl protective groups from compound 6 were removed by catalytic
hydrogenation with palladium on carbon. The reaction was under 65~75 psi hydrogen
pressure for two days. 0.076 ml thionyl chloride was added to 0.167 g Acid-3 (Biofine
International Inc.,Vancouver, Canada) dissolved in 0.32 ml ethyl acetate and 0.1 ml
dimethylformamide and stirred for 5 hr at 50°C. The activation of Acid-3 was completed
under nitrogen atmosphere. 0.25 g deprotected compound 7 and 0.28 g sodium
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bicarbonate were dissolved in ethyl acetate/water (1:1, v/v). The activated Acid-3 was
transferred to the compound 7 by syringe and stirred at room temperature for 1 hr. The
final compound 8 in the organic layer was washed with 5% (w/v) sodium bicarbonate
solution and water sequentially. The dry final product (compound 8) was 0.2 g. The
products of each reaction were confirmed by mass spectrometry.

2.2 Protein expression and purification
Table 6.1 lists the protein sequences of MDR HIV-1 proteases. Active and inactive
MDR HIV-1 protease genes were codon optimized for E. coli expression with the
software DNA 2.0 (76), synthesized by GENEART, Inc. (Regensburg, Germany), and
inserted into the pET21b plasmid. The inactive MDR 769 82T protease had an active site
mutation, D25N, to eliminate catalytic activity. To prevent auto-proteolyses, the Q7K
mutation was introduced into the active MDR HIV-1 protease gene. All MDR HIV-1
proteases were expressed in the E. coli strain BL21 (DE3) pLysE. E. coli cells were lysed
by sonication. The HIV-1 protease expressed in inclusion bodies was separated by
centrifugation and dissolved in a buffer of 50 mM Tris, 25 mM sodium chloride, 0.2%
β-mercaptoethanol, and 6 M urea. The dissolved HIV-1 protease variants were purified
using a Q-Sepharose ion exchange column (Amersham Biosciences, Piscataway, NJ)
pre-equilibrated with the buffer containing 6 M urea. The optimal buffer pH varied from
7.8-8.6 for each of the protease variants. The flow-through containing the pure HIV-1
protease was refolded in the dialysis buffer (20 mM sodium phosphate, 0.2%
β-mercaptoethanol, and 10% glycerol) with step-wise decreases in urea concentration.
The final protein buffer was 20 mM sodium acetate, pH 5.0, 1 mM dithiothreitol (DTT),
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and 10% (v/v) glycerol. The proteases prepared for crystallization were concentrated to
1.5 mg/ml using Amicon concentrators with a 5-kDa molecular mass cut-off (Millipore
Corporate, Billerica, MA).

2.3 Protease inhibition assays
HIV protease Forster Resonance Energy Transfer (FRET) substrate I, purchased
from AnaSpec, Inc. (Fremont, CA, USA), was used in the half-maximal inhibitory
concentration (IC50) determination experiments. The FDA-approved HIV-1 protease
inhibitors were kindly provided by the NIH AIDS Research and Reference Reagent
Program (www.aidsreagent.org). The CA/p2 pseudo peptide with a reduced scissile
peptide bond [-ψ(CH2NH)-] was synthesized in the Department of Chemistry, Wayne
State University. The fluorescence emitted by substrate cleavage was monitored by a
microplate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA) at a 340 nm
excitation wavelength with an emission wavelength of 490 nm. The HIV-1 protease
reaction buffer was adjusted to pH 4.7 [0.1 M sodium acetate, 1.0 M sodium chloride, 1.0
mM ethylenediaminetetraacetic acid (EDTA), 1.0 mM DTT, 10% dimethylsulfoxide
(DMSO), and 1mg/ml bovine serum albumin (BSA)]. In the reaction buffer containing 5
µM FRET substrates, the concentration of all the HIV-1 proteases used in the enzyme
assays was adjusted to a substrate cleavage velocity of 0.08 Relative Fluorescence Units
(RFU)/sec. The final HIV-1 protease concentration was approximately 7 nM. The
protease inhibitor was serially diluted in DMSO from 10 µM to 0.013 nM. The protease
variants and inhibitors were pre-incubated at 37°C for 20 min prior to signal monitoring.
An enzyme-free control was tested as the background substrate fluorescent signal. The
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progress of the reaction was monitored over 20 min sampling fluorescence at 1 min
intervals. The FRET data were plotted with the software SoftMax Pro V5.2 (Molecular
Devices, Sunnyvale, CA) to determine the IC50 values. The difference in Gibbs free
energy (∆∆G) was calculated from the formula ∆∆G = −RT ln[IC50(MDR)/IC50(WT)],
where the IC50(MDR) is the IC50 value inhibiting the MDR HIV-1 protease and the
IC50(WT) is the IC50 value inhibiting the wild-type (WT) HIV-1 protease.

2.4 HIV-1 Protease substrate interference assays
In the enzyme reaction buffer, a regular HIV-1 protease substrate, a heptapeptide,
was mixed with the FRET HIV-1 protease substrate (AnaSpec Inc., Fremont, CA) to
reach a final concentration of 100 µM regular substrate and 2.5 µM FRET substrate. The
nine substrate hepta-peptides were purchase from SynBioSci Corporation, Livermore, CA
(Table 6.2). All the hepta-peptides were purified by HPLC to a purity higher than 98%.
The procedure of substrate interference assay was similar to the protease inhibition assay
except that the inhibitor was replaced by a regular peptide substrate. The HIV-1 protease
reaction buffer was 0.1 M sodium acetate, 1.0 M sodium chloride, 1.0 mM
ethylenediaminetetraacetic acid (EDTA), 1.0 mM DTT, 10% dimethylsulfoxide (DMSO),
and 1mg/ml bovine serum albumin (BSA) at pH 4.7. Upon the addition of the HIV-1
protease, the fluorescent signal emitted through the cleavage of the FRET substrate was
recorded using a SpectraMax M5 instrument (Molecular Devices, Sunnyvale, CA, USA)
at an excitation wavelength of 340 nm and an emission wavelength of 490 nm. The
protease concentration was adjusted to a substrate cleavage velocity of 0.08 RFU/sec in
the absence of regular (non-fluorescent) substrate. In the enzyme reaction buffer, a regular
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HIV-1 protease substrate was mixed with the FRET HIV-1 protease substrate to reach a
final concentration of 100 µM and 2.5 µM, respectively. The average velocity of FRET
substrate cleavage in RFU/min was calculated based on fluorescent signals at 30 time
points over 30 min. In the control experiment, the average velocity of FRET substrate
cleavage was determined in the absence of regular substrate. The result was illustrated by
a bar chart representing the ratio of the average FRET substrate cleavage velocity in the
presence of a regular substrate over the average FRET substrate cleavage velocity in the
absence of a regular substrate.

2.5 Crystallization and diffraction data collection
Inhibitors (tipranavir and darunavir) and substrates (p2/NC and CA/p2) were
co-crystallized with the MDR769 82T inactive protease using the hanging drop vapor
diffusion method. The expression levels of the active MDR protease variants were
generally lower than the expression levels of the inactive enzymes, and the protein
amount of the active MDR protease variants was insufficient for crystallization
experiments. The protease and ligand were pre-mixed at a molar ratio of 1:20 before
crystallization set-up. The protease-ligand solution was then mixed at 2:1 v/v ratio with
the precipitant solution. The optimal crystallization condition was obtained from a set of
precipitant solutions (0.1 M citric acid/MES/HEPES and 0.8~2.8 M ammonium sulfate at
pH 4.0~6.0). The reservoir volume was 750 µl. The MDR 769 82T-p2/NC complex was
crystallized from 0.1 M citric acid and 2.4 M ammonium sulfate at pH 5.2 while the
MDR 769 82T-CA/p2 complex, MDR 769 82T-darunavir complex, and MDR 769
82T-tipranavir complex were crystallized from 0.1 M MES and 2.4 M ammonium sulfate
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at pH 6.0. The reservoir volume was 750 µl. Needle shaped crystals grew to a suitable
size for diffraction within a week. The crystals were placed in a 30% w/v glucose
cryoprotectant solution before they were frozen in liquid nitrogen. The diffraction data
were collected at the Life Sciences Collaborative Access Team (LS-CAT) at the Advanced
Photon Source (APS) Sector 21, Argonne National Laboratory (Argonne, IL, USA) and
the diffraction data were processed with the HKL2000 program suite (77).

2.6 Structure refinement and analysis
Molecular replacement was performed with the CCP4 program Molrep-autoMR (78).
A previously solved HIV-1 protease structure was used as the search model for molecular
replacement. The models of darunavir and tipranavir were built with the program COOT
(79) using a ligand finding algorithm where the molecular formulas of the inhibitors were
provided in SMILES representation. The protease-ligand model was further refined using
the program Refmac5. The tipranavir molecules were refined in two orientations with
half-occupancy while the darunavir molecule was refined in one orientation with
full-occupancy. Restrained anisotropic refinement was used for the tipranavir-MDR 769
82T co-crystal structure. The structure was validated using Procheck V3.4.4 (80). The
models of tipranavir or darunavir complexed with MDR 769 82T were analyzed for
molecular interaction using the program LIGPLOT V4.5.3 (81).
The

co-crystal

structures

were

deposited

in

the

Protein

Data

Bank

(http://www.pdb.org/). The accession codes for the darunavir-MDR 769 82T complex and
the tipranavir-MDR 769 82T complex are 3SO9 and 3SPK, respectively.
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2.7 Virtual screening and protein-compound docking studies
The large scale screening was conducted using a fast pre-screening tool, eHiTS
LASSO (Ligand Activity in Surface Similarity Order) 2009 (82). Compound libraries
were downloaded from the ZINC database of commercially-available compounds
(http://zinc.docking.org/).
The chemical structure of compound GR346 was drawn in the program
ChemBioDraw Ultra 12.0. The three-dimensional structure of GR346 was obtained by
energy

minimization

using

the

GlycoBioChem

PRODRG2

Server

(http://davapc1.bioch.dundee.ac.uk/prodrg/). The electrostatic descriptor gasteiger charges
were added to atoms of protein and ligand.
To examine the binding of the lead compound from virtual screening, the compound
was docked into the binding pocket of HIV-1 protease using the program AutoDock4
(83).

2.8 Differential scanning fluorimetry
Differential scanning fluorimetry (DSF) was used to detect the protein melting
temperature change after ligand binding (84). The bigger the melting temperature change,
the tighter the ligand binding. A modified procedure is described as follows. The HIV-1
protease was diluted in the buffer of 100 mM Sodium acetate-AcOH and 150 mM NaCl at
pH 5.0 to reach a final concentration of 0.4 mg/ml. The protease solution was
pre-incubated with 500 µM protease inhibitors. 5×SYPRO orange dye (stock
concentration 5,000×, Sigma-Aldrich, Inc., Saint Louis, Missouri, USA) was added to the
protease-inhibitor mixture. The protein-dye solution (100 µl) was heated from 25°C to
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82°C. During the heating process, the fluorescence signal was read using a microplate
reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA) with the excitation and
emission wavelength at 492 nM and 610 nM, respectively.

2.9 Initial model preparation for molecular simulation
The X-ray structures of the protease-substrate complex (MDR 769 in complex with
the substrate p2/NC) is solved and used as an initial structure for homology modeling.
The complexes of MDR 807-p2/NC, MDR 1385-p2/NC, MDR 3761-p2/NC, and
NL43-p2/NC were constructed using SWISS-MODEL (85). Similarly, a series of HIV-1
protease-CA/p2 complexes were built based on the MDR 769-CA/p2 co-crystal structure.
Based on the catalytic mechanism of HIV-1 protease, Asp 25 was assigned as a
protonated state while Asp 25’ was assigned as a deprotonated state. All histidine residues
were assigned a neutral charge. Protonation states of other amino acid residues were
assumed based on the buffer pH in the HIV-1 protease enzymatic assays (pH 4.7). To
avoid simulating a catalytic interaction, positional restraints were applied to the scissile
peptide bond of the substrate and the β-carboxyl groups of catalytic residue Asp 25 and
Asp 25’. The HIV protease-substrate complex was placed into an orthogonal TIP3P water
box. The TIP3P is a three-site (three interaction sites) water model, which is one of the
most widely used water models. The protease complex was at least 12 Å from the edge of
the water box. Na+ and Cl- ions were added to neutralize the simulation system.
In the preparation of the NS3/4A HCV protease, the NS3 protease (from residue 1 to
residue 181) and NS4A peptide (from residue 21 to residue 32) of HCV genotype 1b, 4a,
5a, and 6a were modeled based on a structure of HCV NS3/4A protease with a ketoamide
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inhibitor (PDB: 3KN2) using SWISS-MODEL (85). The NS4A peptide binds
non-covalently to the NS3 protease domain. Telaprevir was built with ChemBio3D and
manually superimposed on the ketoamide inhibitor in the crystal structure. As a common
mechanism of ketoamide inhibitors against the HCV protease, telaprevir formed a
covalent bond with the hydroxyl oxygen of the catalytic residue Ser 139. The topology
and force field parameters for telaprevir were initially generated using ParamChem
(https://www.paramchem.org/), the CHARMM General Force Field (CGenFF) program
for automatic atom typing and assignment of parameters and charges by analogy. The
topology file and parameter file of telaprevir were then manually edited to covalently
attach the drug to the Ser 139. Finally, the HCV protease complexes including NS3
protease domain, NS4A peptide, and telaprevir were solvated in a water box where the
edge of the box is no less than 12 angstroms away from the protease complex. The system
was neutralized with Zn2+ and Cl- ions.

2.10 Molecular dynamics simulation
The MD simulations were performed using the parallel computing program Scaling
NAno Molecular Dynamics (NAMD) V. 2.7b (86). The protease complex models were
solvated in a water box using TIP3P models for water molecules. To prevent translational
and rotational displacement and to prevent the simulation of the catalytic reaction,
positional restraints were applied for the carbonyl group of the substrate scissile peptide
bond and the catalytic residue Asp 25 and Asp 25’ of the HIV-1 protease. The cutoff for
non-bonded interactions was 10 Å. Particle Mesh Ewald was implemented; the Particle
Mesh Ewald method calculates direct-space interactions within a finite distance using a
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modification of Coulomb’s law, and in reciprocal space using a Fourier transform to build
a “mesh” of charges, interpolated onto a grid (87). The systems were energy minimized
using a conjugate gradient method and gradually heated from 70K to 310K in 200 ps.
Simulations were conducted at 310K and 1.0 atm (NPT ensemble) for 10 ns using the
CHARMM force field 27 and a timestep of 2 fs.
An example of NAMD configuration commands with annotations is listed as follows.
## Adjustable Parameters
structure

input.psf ; # Specify a protein structure file that contains molecular
characteristics required by a particular force field.

coordinates

input.pdb ; # Specify an atomic coordinate file

set temperature

310 ; # The simulation was conducted at 310 K.

set outputname

output ; # Name the output files

firsttimestep

0 ; # Start the simulation from step 0.

## Simulation Parameters
paraTypeCharmm

on ; # Turn on CHARMM force field.

parameters

Par_all27_prot_na.prm ; # Specify the CHARMM27 parameter
file which define forces and energies for protein, lipid, DNA, and
RNA.

parameters

par_all36_cgenff.prm ; # Specify the CHARMM General Force
Field parameter file for compounds.

temperature

$temperature ; # Read temperature from “temperature” variable.

reassignFreq

2000 ; # Reassign temperature every 2000 steps.
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reassignTemp

70 ; # Increase temperature from 70 K (the liquid nitrogen
temperature).

reassignIncr

5 ; # The temperature increment is 5 K.

reassignHold

310 ; # Hold the temperature at 310 K.

# Force-Field Parameters
exclude

scaled1-4 ; # Four adjacent covalently bonded atoms are excluded from
non-bonded calculations.

1-4scaling

1.0 ; # The constant factor of electrostatic interactions for 1-4 atom pairs.

cutoff

12. ; # The cutoff distance for non-bonded interaction is 12 Å.

switching

on ; # Smoothing functions are applied to both the electrostatics and van der
Waals forces.

switchdist

10. ; # The smoothing function takes effect when atom distance is between
10 and 12 Å.

pairlistdist

13.5 ; # When distance between atoms is less than 13.5 Å in each cycle, the
atom pair is included in pair list for electrostatics and van der Waals
interaction calculation.

margin

2.5 ; # Add 2.5 Å extra length in patch dimension.

# Integrator Parameters
timestep

2.0 ; # The length of each step is 2fs.

rigidBonds

all ; # The bond between hydrogen and its bonded atoms is
constrained.

nonbondedFreq

1 ; # Non-bonded interactions are calculated in every time step.
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fullElectFrequency

2 ; # Full electrostatic interactions are calculated in every 2 time
step.

stepspercycle

10 ; # The interacting particle lists are updated every 10 time step.

# Constant Temperature Control
langevin

on ; # Perform Langevin dynamics to introduce additional damping
and random forces to the system.

langevinDamping

5 ; # Langevin damping coefficient is 5/ps

langevinTemp

$temperature ; # Langevin dynamics adjust the effect on atoms
based on the temperature variable.

langevinHydrogen

off ; # Turn off Langevin dynamics for hydrogen atoms.

# Constant Pressure Control
useGroupPressure

yes ; # Pressure is calculated using hydrogen-group based
pseudo-molecular virial and kinetic energy which results in
smaller fluctuations.

useFlexibleCell

no ; # Do not allow three orthogonal dimensions of the periodic
cell to fluctuate independently.

useConstantRatio

no ; # Do not maintain a constant ratio of the unit cell in the x-y
plane.

langevinPiston

on ; # Turn on Langevin piston pressure control.

langevinPistonTarget

1.01325 ; # The target pressure for Langevin piston method is
1.01325 bar.

langevinPistonPeriod

100 ; # The barostat oscillation time scale for Langevin piston
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method is 100 fs.
langevinPistonDecay

50 ; # The barostat damping time scale for Langevin piston
method is 50 fs.

langevinPistonTemp

$temperature ; # The barostat noise temperature for Langevin
piston method is the same as the temperature specified in
temperature control.

# Output
outputName

$outputname ; Specify the output name for output files.

restartfreq

1000 ; # Prepare the restart files every 1000 steps (2 ps).

dcdfreq

1000 ; # The trajectory file is updated every 1000 steps.

outputEnergies

1000 ; # Output energy to log file every 1000 steps.

outputPressure

1000 ; # Output pressure to log file every 1000 steps.

#Harmonic constraints
constraints

on ; # Turn on positional restraints.

consexp

2 ; # Use 2 as an exponent for constraint energy function

conskcol

B ; # Specify the B factor column of the PDB file to use for the harmonic
constraint force constant.

consref

constraint.pdb ; # Input the PDB file indicating constraint atoms.

conskfile

constraint.pdb ; # Input the PDB file to use for force constants for harmonic
constraints.

## Extra Parameters
# Periodic Boundary Conditions
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cellBasisVector1 80.16 0.0 0.0 ; # Specify the x-dimension of the periodic cell size in Å.
cellBasisVector2 0.0 63.51 0.0 ; # Specify the y-dimension of the periodic cell size in Å.
cellBasisVector3 0.0 0.0 64.93 ; # Specify the z-dimension of the periodic cell size in Å.
cellOrigin

5.26 1.74 16.96 ; # Specify the position of the periodic cell center.

wrapWater

on ; # When water molecules cross a periodic boundary, they are not
translated to the other side of the periodic cell.

wrapAll

on ; # When a molecule cross a periodic boundary, it is not translated to
the other side of the periodic cell.

# PME Particle Mesh Ewald
PME

yes ; # Turn on Particle Mesh Ewald method, an efficient full
electrostatics method in periodic boundary conditions.

PMEGridSizeX

90 ; # Number of grid points in X dimension.

PMEGridSizeY

72 ; # Number of grid points in Y dimension.

PMEGridSizeZ

72 ; # Number of grid points in Z dimension.

## Execution Script
# Minimization
minimize

10000 ; # Run 10,000 step conjugate gradient energy minimization.

reinitvels

$temperature ; # Reset the temperature according to the temperature
variable after minimization

# Molecular Dynamics
run

7500000 ; # Run molecular dynamics for 7500000 steps, which is equal to
15000 ps (15 ns)
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2.10.1 The CHARMM force field
The CHARMM (Chemistry at HARvard Macromolecular Mechanics) force fields
represent a set of widely used force fields in molecular dynamics. The CHARMM19 and
CHARMM22 force fields are parameterized for proteins, and the CHARMM27 force
field is parameterized for lipid, DNA, and RNA. A general force field for drug-like
molecules (CGenFF) covers a wide range of chemical groups.
The following equation is the potential energy function from CHARMM22 (88):
Utotal = Ubond + Uangle + Udihedral + UvdW + UCoulomb. The components of the potential energy
function in this equation contain the energy functions for bond stretching, bond angle
bending, torsion (dihedral angle), and nonbonded interaction. The nonbonded interactions
include van der Waals (vdW) energy and electrostatic (Coulomb) energy.

2.11 Data analysis of molecular dynamics results
Trajectories of MD simulation were visualized and analyzed using the Visual
Molecular Dynamics (VMD) program V. 1.91. The superposition of molecular structures
was carried out using Pymol. The root-mean-square deviation (RMSD) values were
calculated using the VMD RMSD trajectory plug-in. The molecular mechanics energy
was calculated using the NAMD energy plug-in in VMD. The final molecular mechanics
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energy is the average of molecular mechanics energy of the last 100 frames (the last 200
ps simulation). Previous studies demonstrated that HIV-1 protease ligands show
single-maxima probability density function of energy (13). Therefore, the last 200 ps
simulation represents a relatively stable protease-ligand complex conformation.
Hydrophobic solvation energy and electrostatic solvation energy were calculated and
averaged based on the 10 snapshot coordinates of the last 200 ps simulation.
The change in desolvation energy during the binding of protease to its substrate was
obtained with the following equation, ∆Gsolv = ∆Gdesolvelectrostatic + ∆Gdesolvnonpolar. The
electrostatic desolvation energy was calculated using the Adaptive Poisson-Boltzmann
Solver (APBS) program (89), a software package for modeling biomolecular solvation
through solution of the Poisson-Boltzmann equation (PBE). The electrostatic desolvation
energy upon protease-substrate complex formation was calculated using the following
equation, ∆Gdesolvelec = ∆∆Gsolvelec = ∆Gsolvelec,complex – ∆Gsolvelec,protease – ∆Gsolvelec,substrate. The
symbol ∆Gsolv refers to the difference of solvation energy when a molecule is transferred
from water solution (with a dielectric constant of 78.54) to vacuum (with a dielectric
constant of 1.00). The symbol ∆∆Gsolvelec represents the solvation energy change
(desolvation energy) upon protease-substrate complex formation. The input for the APBS
program was prepared by converting the PDB format coordinate to PQR format through
the PDB2PQR server (http://propka.ki.ku.dk), an automated pipeline for the setup,
execution, and analysis of Poisson-Boltzmann electrostatics calculations (90). The
PDB2PQR server adds charge and radius parameters to existing PDB data. The non-polar
desolvation energy was calculated using the equation ∆Gdesolvnonpolar = –∆Gsolvnonpolar = –
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(γ∆SASA + β), where SASA stands for solvent accessible surface area, γ is a standard
value of 0.00542 kcal*mol−1*Å−2, and β is 0.92 kcal mol−1 (91). The change of solvent
accessible surface area upon protease-substrate complex formation is calculated using the
following equation, ∆SASA = SASAcomplex – SASAprotease – SASAsubstrate.

2.12 Determination of representative sequences for genotype 4, 5 and
6 HCV NS3/4 proteases
All available NS3/4A protease sequences from the HCV database (http://hcv.lanl.gov)
were aligned using the ClustalW2 program (http://www.ebi.ac.uk/Tools/clustalw2) to find
a patient isolate sequence that is closest to the consensus sequence of each HCV genotype.
That patient isolate sequence was selected as the representative for a particular HCV
genotype.

2.13 Expression of the NS3/4A proteases of the HCV genotype 4, 5,
and 6
Based on the representative sequences of the HCV genotype 4 to 6, the fusion genes
were constructed with the residues 3-181 of NS3 protein and the residues 21-32 of NS4A
protein fused to the N-terminus of NS3 protease domain. Therefore, the HCV NS3/4A
protease maintains an active form without the need for the addition of a separate NS3/4A
peptide. Between NS4A and NS3, there is a four-residue flexible GSGS linker. Since the
essential fragment (residue 21-32) of the NS4A peptide has been identified (92), and
previous studies showed that the fusion protein containing NS4A (residue 21-32), NS3
(residue 3-181) and a tetrapeptide linker (GSGS) exhibited the full proteolytic activity
(93), the fusion protein is used in this study to facilitate enzyme assays and crystallization
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studies later on. For the final constructs, the NS3/4A fusion genes were inserted into the
plasmid pET28b(+) which produced a 21-residue thrombin cleavable His-tag
(MGSSHHHHHHSSGLVPRGSHM) at the N-terminus. The 216 amino acid fusion
proteins (~23 kDa) with NS3 protease domain, a fragment of the NS4A protein, the
GSGS linker, and the thrombin cleavable His-tag were expressed and purified by
AnaSpec, Inc. (San Jose, CA). The thrombin cleavable His-tag was kept in the final
protein since studies conducted at AnaSpec, Inc. showed an increased enzyme activity by
keeping the tag.

2.14 HCV protease inhibition essays
The enzyme inhibitory activity of telaprevir, IC50, for HCV NS3/4A protease from
genotype 4 to 6 was evaluated. HCV protease FRET substrate S-1 was purchased from
AnaSpec, Inc. The fluorescence emitted by the peptide cleavage was monitored by
microplate reader (SpectraMax M5, Molecular Devices) using the excitation wavelength
355 nm and the emission wavelength of 495 nm. There is no intermolecular quenching of
the FRET peptide observed in the concentration range of 0.5 to 7.0 µM. The optimized
concentration of protease was obtained by adjusting the FRET substrate cleavage speed to
0.08 RFUs/sec. The experiments were conducted in a 96-well plate, with each well
containing a constant amount of NS3/4A protease in the assay buffer and varying
concentrations of the serially diluted telaprevir. After a 1 hour incubation at 37°C to form
the tight enzyme-inhibitor complex-telaprevir being a slow, tight-binding inhibitor – the
reaction was initiated by the addition of the FRET substrate S1 (final concentrations of 5
µM S1, 2% (vol/vol) DMSO, total assay volume was 100 µl). The reason for
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slow-binding inhibition by telaprevir is not known. In contrast, incubation of the HIV-1
protease with any of the licensed drugs prior to substrate addition is not needed. The
progress of the HCV NS3 reactions was monitored over 20 min using a sampling rate of 1
min. The FRET substrate cleavage rates (initial velocities) of the NS3/4 protease with
serially diluted telaprevir were plotted as data points with the software of SoftMax Pro V.
5.2.

46

CHAPTER 3 DESIGN AND SYNTHESIS OF A
MULTI-DRUG RESISTANT HIV-1 PROTEASE
INHIBITOR BASED ON LOPINAVIR

3.1 Introduction
Developing novel HIV-1 protease inhibitors that overcome drug-resistance is still a
challenging task. In drug development, it is difficult to keep pace with the emergence of
drug resistance. Compared to de novo drug design, drug modification and optimization
could lower the risk of failure in clinical trials. The modification of available protease
inhibitors according to the MDR HIV-1 protease isolate may provide a solution to
overcome drug resistance. Lopinavir is a second-generation protease inhibitor, which is
derived from ritonavir. The smaller P2 and P2’ groups of lopinavir decrease the contact
with highly variable residues at the 82 site HIV-1 protease and improve the inhibitory
efficacy against drug-resistant mutants of HIV-1 protease (19). The MDR HIV-1 protease
isolate 769 exhibits cross resistance to HIV-1 protease inhibitors. Though lopinavir
inhibits MDR 769 with a low relative resistance, further modification of lopinavir may
improve its efficacy against drug resistance mutations in the HIV protease. A mutagenesis
experiment has been recently completed in our laboratory. The P1 and P1’ groups of the
HIV-1 protease substrate CA/p2 possessing a reduced scissile peptide bond have been
mutated

and

tested

for

HIV-1

protease

inhibition.

Compared

to

a

phenylalanine-phenylalanine combination at P1 and P1’ sites, the combination of leucine
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at the P1 site and phenylalanine at the P1’ site exhibits relatively high inhibitory efficacy
and reduced relative resistance against MDR769 (unpublished data). The current first line
protease inhibitor, darunavir, also contains the asymmetric combination of leucine side
chain and phenylalanine side chain at the P1’ and P1 sites (28). However, lopinavir carries
the symmetric P1 and P1’ groups mimicking the phenylalanine side chain. Therefore, by
changing the P1 site of lopinavir from a phenylalanine side chain to a leucine side chain
(isobutyl group), the inhibitory potency of the modified lopinavir may increase and the
relative resistance against MDR protease may decrease.

In this chapter, the synthesis, inhibitory potency, and binding mechanism of a
lopinavir analog with isobutyl P1 group is discussed. The lopinavir analog lowers the
relative resistance against an MDR HIV-1 protease variant. Simulation results indicate
that the lopinavir analog induces an asymmetric movement of the 80s loop of the MDR
HIV-1 protease and this analog exhibits a stronger interaction energy.
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P1

P1’

CA/p2 (P1F, P1’F) reduced peptide

P1

P1’

CA/p2 (P1’F) reduced peptide
P1

P1

P1’

P1’

lopinavir

lopinavir analog
P1

P1’
darunavir

Figure 3.1 Chemical structures of compounds discussed in Chapter 3. The reduced
peptide bonds, P1, and P1’ groups are labeled in the figure.
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3.2 Results
3.2.1 Isobutyl P1 lopinavir analog reduced the relative resistance against the MDR
HIV-1 protease 769
A lopinavir analog with isobutyl P1 group was chemically synthesized according to
the synthesis procedure of lopinavir (Figure 2.1). The modified step was the Grignard
reaction, where 1-chloro-2-methyl propane was used to replace benzyl chloride in order
to introduce a leucine side chain rather than a phenylalanine side chain to the lopinavir
analog. The original lopinavir was synthesized in parallel as a control. The final lopinavir
analog was verified using electrospray mass spectrometry (Figure 3.2). The major
impurity is an intermediate product.
The IC50 of lopinavir analog with an isobutyl P1 group was determined and listed in
Table 3.1. The IC50 of the synthesized original lopinavir control and the CA/p2 reduced
peptide (P1’F) were also measured. The lopinavir analog achieved 50% inhibition of the
WT HIV-1 protease and MDR 769 at the concentration of 2.1±0.1 nM and 6.8±0.4 nM,
respectively. The inhibition efficacy of the lopinavir analog was higher than the lopinavir
control synthesized in parallel which exhibited the IC50 values of 2.5±0.5 nM and 16±0.6
nM for the WT HIV-1 protease and MDR 769, respectively. Furthermore, the lopinavir
analog decreased the relative drug resistance from 6.4 to 3.2. The CA/p2 reduced peptide
still showed the lowest IC50 value (4.4±0.2 nM) inhibiting the MDR HIV-1 protease as
well as having the lowest relative resistance (1.7 fold).

50

Table 3.1 IC50 results with the lopinavir analog
HIV-1 protease
NL4-3

MDR 769

Relative
resistance

Synthesized lopinavir analog

2.1±0.1

6.8±0.4

3.2

Synthesized lopinavir control*

2.5±0.5

16±0.6

6.4

Reduced CA/p2 (P1’F) peptide

2.6±0.4

4.4±0.2

1.7

30.7

142

4.6

Compounds (nM)

Reduced CA/p2 (P1F, P1’F) peptide

*The lopinavir control was synthesized in parallel using the same procedures and
equipments. The only different reagent is benzyl chloride instead of 1-chloro-2-methyl
propane.

+ K+
lopinavir analog

OH

+ Li+

O

HN

N
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lopinavir analog

+ H+
lopinavir analog

+ Na+
lopinavir analog

Figure 3.2 Electrospray mass spectrometry results of the lopinavir analog. Samples were analyzed with K+, Li+, and Na+ ions.

52

3.2.2 Asymmetric P1 and P1’ groups induce asymmetric 80s loop conformations of
the MDR HIV-1 protease 769
The combination of isobutyl and benzyl group as P1 and P1' sites could induce an
asymmetric movement of the mobile 80s loops of the HIV-1 protease. By examining the
co-crystal structures of CA/p2 or darunavir with MDR 769 A82T, the P1 leucine residue
of CA/p2 peptide and the P1’ isobutyl group of darunavir brought the Pro 81 residue on
the 80s loop of HIV-1 protease closer to the ligand. In Figure 3.3, the MDR 769
82T-CA/p2 complex crystal structure and MDR 769 82T-darunavir complex crystal
structure were superimposed to a WT HIV-1 protease-lopinavir complex crystal structure.
Compared to the protease 80s loops interacting with the symmetric P1 and P1’ benzyl
groups of lopinavir, the P1 leucine of CA/p2 peptide brought the protease 80s loop closer
to the P1 group (Figure 3.3 A) while the phenylalanine P1’ group of the CA/p2 peptide
induced a similar loop conformation as that of the lopinavir complex (Figure 3.3 B). The
asymmetric conformations of protease 80s loops have also been observed in the MDR
769 82T-darunavir complex due to the asymmetric P1 (benzyl) and P1’ (isobutyl) groups
of darunavir
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Pro 81

Pro 181

P1
A

B

P1’

Pro 81

Pro 181

P1’
C

P1
D

Figure 3.3 The benzyl and isobutyl groups at P1 and P1’ sites trigger the asymmetric
80s loop conformation of the MDR HIV-1 protease. (A) The co-crystal structure of
CA/p2 with MDR 769 82T (grey) was superimposed on the co-crystal structure of
lopinavir with the WT HIV-1 protease (sliver, PDB 2Q5K). The P1 leucine side chain of
CA/p2 interacted with the protease and altered the 80s loop conformation of one MDR
protease monomer. (B) In the CA/p2-MDR 769 structure (grey), the P1’ phenylalanine
side chain of CA/p2 did not alter the 80s loop conformation of the MDR HIV-1 protease,
compared to the lopinavir-WT HIV-1 protease co-crystal structure (white). (C) The
co-crystal structure of darunavir with MDR 769 82T (grey, PDB 3SO9) was
superimposed to the co-crystal structure of the lopinavir-MDR 769 82T complex (white).
The P1’ isobutyl group of darunavir triggered a similar conformation of the 80s loop as
that triggered by the P1 leucine side chain of the CA/p2. (D) The 80s loop conformation
that interacted with the P1 benzyl group was conserved in the lopinavir-MDR 769 82T
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(white) and the darunavir-MDR 769 82T (grey) complex structures.
3.2.3 Simulation analysis of the lopinavir analog binding to the MDR HIV-1 protease
The lopinavir and isobutyl P1 lopinavir analog in complex with MDR 769 were
modeled and simulated for 10 ns. The average conformations of the last 200 ps simulation
were analyzed for both the lopinavir and lopinavir analog complexes. In the average
conformation of the MDR 769-lopinavir complex, the asymmetric conformation of
protease 80s loops was observed as well. One 80s loop of the MDR HIV-1 protease 769
moved closer to the isobutyl P1 group of the lopinavir analog (Figure 3.4). The
interaction energy calculated between the inhibitor and protease was listed in Table 3.2.
The calculated interaction energy suggested that the lopinavir analog interacted with
MDR 769 stronger (-99.47 kcal/mol) than lopinavir did (-92.39 kcal/mol). The interaction
energy was increased in both electrostatic interactions and van der Waals interactions.

Pro 81
80s loop

80s loop

Figure 3.4 Isobutyl P1 lopinavir analog induces asymmetric 80s loop conformation
of MDR HIV-1 protease 769. The MDR 769-lopinaivr model is represented in while,
and the MDR 769-lopinaivr analog model is represented in black. The HIV-1 proteases
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are shown in ribbon representation while the inhibitors and the proline 81 are shown in
stick representation.
Table 3.2 Interaction energy of lopinavir and lopinavir analog with the multi-drug
resistant HIV-1 protease 769
Interaction energy (kcal/mol)
Compounds
Electrostatic

Van der Waals

Nonbonded (total)

lopinavir analog

-37.39±6.55

-62.08±3.57

-99.47±7.45

lopinavir

-32.27±8.57

-60.12±3.76

-92.39±9.34

3.3 Discussion
The drug-resistant mutations may increase the flexibility of HIV-1 protease and
therefore alter the active site conformation to be unfavorable for drug binding. The 80s
loop is a mutation hot spot of HIV-1 protease, which directly interact with the P1 and P1’
group of substrates or drugs. The V82A/C/F/I/L/M/S/T mutations on the loop have been
identified (15, 94). Both structural analyses and enzymatic results indicate that a smaller
P1 or P1’ group, such as leucine, brings the 80s loop closer to the ligand and increases
binding affinity.
The enzyme inhibitory assays demonstrate the promising role of an isobutyl group at
the P1 or P1’ position in overcoming drug-resistance. However, due to the limitation of
purification techniques, neither the lopinavir analog or lopinavir control reach the potency
of the standard lopinavir that was requested from the NIH AIDS Research and Reference
Reagent Program. The impurities and stereoisomers mixed in the final products increase
the IC50 values.
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Furthermore, the lopinavir analog does not reach the inhibitory potency of CA/p2
P1’F reduced peptide against the MDR 769 protease. The potency of CA/p2 P1’F reduced
peptide may be influenced by the P2’ glutamic acid. Studies have shown that the binding
efficacy of reduced peptides with a glutamic acid in the P2’ position are pH-sensitive (95).
Therefore, the electrostatic interactions of the CA/p2 P1’F reduced peptide is superior to
the hydrophobic lopinavir analog, which explains the relatively lower potency of
lopinavir analog compared to the CA/p2 P1’F reduced peptide.
The lopinavir analog with an isobutyl group at the P1 position may serve as an
HIV-1 protease inhibitor against MDR proteases, especially MDR HIV-1 proteases
containing mutations on the 80s loops. Currently, genotypic assays are recommended to
assess resistance in the adult and adolescent guidelines of antiretroviral treatment (28).
Benefiting from protease gene sequences of patience isolates, the choice of optimal
regimen could be decided based on the types of drug-resistance mutations. Therefore,
there is a demand of developing modified protease inhibitors against various groups of
HIV-1 protease variants.

3.4 Author’s contribution
The author synthesized the lopinavir analog and lopinavir control, carried out the
HIV-1 protease inhibition assays and molecular dynamics simulations. The analysis of the
results including structure superposition was also carried out by the author.
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CHAPTER 4 THE HIGHER BARRIER OF DARUNAVIR
AND TIPRANAVIR RESISTANCE FOR HIV-1
PROTEASE

4.1 Introduction
The emergence of drug resistance during antiretroviral therapy is a key concern for
HIV patients. In patients undergoing combination antiretroviral therapy, protease
inhibitors are important contributors to the decrease in the number of circulating virus
particles. In total, nine HIV-1 protease inhibitors have been approved by the US Food and
Drug Administration (FDA). In the 99 amino acid residue HIV-1 protease, 36 mutation
loci have been identified which lead to various levels of resistance to protease inhibitor
treatment (15, 96). The current HIV-1 protease inhibitors are designed with a hydroxyl
group to mimic the transition state of the substrate’s scissile peptide bond. Due to the
structural similarity of inhibitors, the mutations in HIV-1 protease are commonly
associated with cross-resistance to the other inhibitors (94).
The clinical multi-drug resistant (MDR) HIV-1 strain 769 was isolated by Palmer et
al. from patients failing protease inhibitor-containing antiretroviral regimens, and the
protease of strain 769, MDR 769, is resistant to all protease inhibitors tested (97). As
observed in the crystal structure previously solved by our group, the flaps of MDR 769
are farther apart compared to the distance of wild-type (WT) HIV-1 protease flaps (98).
The threonine mutation at residue 82 of the MDR HIV-1 protease (MDR 769 82T) alters
the hydrophobicity of the P1 and P1’ binding pockets and could further enhance
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cross-drug resistance. The uncomplexed MDR 769 82T crystal structure adopts the
wide-open flap conformation as reported earlier for MDR 769 (98, 99).
According to virologic response studies, darunavir and tipranavir show a higher
genetic barrier to resistance (100). Both inhibitors have been used to treat patients
infected with protease inhibitor-resistant viral strains and have effectively inhibited a
range of MDR protease isolates (101-103). Based on the scoring function of the HIV
Drug Resistance Database (http://hivdb.stanford.edu), MDR 769 82T has low resistance
to darunavir and high resistance to tipranavir as well as the other seven protease inhibitors
(15, 96).
The structural study of the inhibitor-bound MDR HIV-1 protease facilitates the
understanding of drug resistance mechanisms. The aim of this study is to test the in vitro
inhibitory potency of darunavir and tipranavir against MDR 769 82T and to determine the
mechanism of overcoming resistance by examining the binding conformation, key
contacts, and the stability of inhibitor-protease complexes. The protease inhibition assays
demonstrate the decreased susceptibility of MDR 769 82T to all the tested inhibitors and
confirm that 82T severely enhances drug resistance. Compared to other protease
inhibitors, the higher resistance barrier of darunavir is due to maintaining main chain
hydrogen bonds by inhibitor flexibility while the higher resistance barrier of tipranavir is
due to tight flap binding.

Table 4.1 Sequences of the HIV-1 protease variants
HIV-1
protease
NL4-3
MDR 769
MDR 769 82T
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a

Sequencesa
PQITLWKRPL
PVNIIGRNLL
PQITLWKRPI
PANVIGRNLM
PQITLWKRPI
PTNVIGRNLM

VTIKIGGQLK EALLDTGADD TVLEEMNLPG RWKPKMIGGI GGFIKVRQYD QILIEICGHK AIGTVLVGPT
TQIGCTLNF
VTIKIGGQLK EALLDTGADD TVLEEVNLPG RWKPKLIGGI GGFVKVRQYD QVPIEICGHK VIGTVLVGPT
TQIGCTLNF
VTIKIGGQLK EALLDTGADD TVLEEVNLPG RWKPKLIGGI GGFVKVRQYD QVPIEICGHK VIGTVLVGPT
TQIGCTLNF

The drug resistant mutations are in bold and polymorphic changes are underlined.

Table 4.2 IC50 measurements and relative resistance
IC50 (nM)

Relative resistance

Predicted
resistance scorea

Inhibitor
MDR 769

MDR 769
82T

MDR
769

MDR 769
82T

MDR
769

MDR
769 82T

darunavir

0.26 ±0.024

0.74 ±0.20

2.76 ±0.16

2.8

11

10

10

tipranavir

0.24 ±0.18

0.63 ±0.17

3.02 ±0.10

2.6

13

24

64

lopinavir

0.28 ±0.27

0.50 ±0.060

3.18 ±0.23

1.8

11

76

76

amprenavir

0.43 ±0.044

4.82 ±0.90

7.87 ±0.16

11

18

86

86

atazanavir

0.19 ±0.071

2.90 ± 0.16

10.8 ±0.40

15

57

98

103

nelfinavir

1.58 ±0.85

109 ±5.0

448 ±65

69

2.8×102

184

184

ritonavir

0.34 ±0.15

60.7 ±3.5

237 ±5.6

180

7.0×102

-

-

saquinavir

0.50 ±0.017

294 ±9.4

1.30×103 ±87

590

2.6×103

114

114

indinavir

0.47±0.19

119 ± 13

307 ±29

250

6.5×102

128

128

60

WT (NL4-3)

a

The resistance scores for darunavir, tipranavir, lopinavir, amprenavir, atazanavir, saquinavir, and indinavir were predicted based on the protease

inhibitor plus ritonavir co-administration. The larger scores indicate higher predicted resistance.
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4.2 Results
4.2.1 Darunavir and tipranavir presented high barrier of resistance compared to the
other protease inhibitors
The nine FDA-approved HIV-1 protease inhibitors were effective against the WT
HIV-1 protease, NL4-3, at low nanomolar or sub-nanomolar concentration while the
MDR 769 82T was resistant to all nine inhibitors (Table 4.2). The resistance ranged from
11-fold to 2600-fold as compared with the inhibition level against NL4-3. Although 11-13
relative resistance was observed, darunavir and tipranavir were the two most potent
inhibitors against MDR 769 82T. Based on the IC50 values, the difference in Gibbs free
energy (∆∆G) values calculated with the IC50 of MDR 769 82T and WT HIV-1 protease
were -1.48 kcal/mol and -1.58 kcal/mol for darunavir and tipranavir, respectively.
The 82T mutation of the MDR protease greatly enhanced drug resistance. The
relative resistance of the MDR 769 (1.8-590 fold) was approximately 2.6-6.1 times lower
compared to that of MDR 769 82T. The 82T mutation caused relatively larger differences
in the relative resistance of darunavir, tipranavir, and lopinavir, and the relative resistance
was elevated 3.9, 5.0, and 6.1 times, respectively. The IC50 values are not fully correlated
with predicted values based on the scoring of inhibitor resistance mutations from the HIV
Drug Resistance Database since the 82T mutation has not been reported previously as
darunavir resistance mutation (104).

4.2.2 Darunavir or tipranavir induced flap closure of the MDR HIV-1 protease
The darunavir-MDR 769 82T and tipranavir-MDR 769 82T co-crystal structures
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were determined at a resolution of 1.24 Å and 2.87 Å, respectively. The binding of
tipranavir or darunavir effectively closed the wide-open flap of the MDR protease and
exhibited a conserved binding mode in the MDR protease relative to that in the wild-type
protease. The tipranavir-MDR 769 82T complex crystallized in the hexagonal space
group P61. The darunavir-MDR 769 82T complex crystallized in the orthorhombic space
group P212121. The diffraction and refinement statistics are shown in Table 4.3. The
structures were deposited in the Protein Data Bank. The PDB IDs for darunavir-MDR 769
82T and tipranavir-MDR 769 82T structures are 3SO9 and 3SPK, respectively. Compared
with the binding of darunavir or tipranavir to the WT HIV-1 protease (PDB ID: 3BVB
and 2O4P), the butyl group of tipranavir and the P1’, P2, and P2’ groups of darunavir
adopted different conformations relative to their binding to WT HIV-1 protease (Figure
4.1 A and B).
Asymmetric movement of the 80s loop regions was observed in the darunavir-MDR
complex. The RMSD of Thr 82 of superimposed protease monomers is 1.318 Å. The
asymmetric P1 and P1’ group of darunavir induced the asymmetric protease dimer. The
smaller isobutyl P1’ group of darunavir allowed the 80s loop of the MDR protease to
move closer to the inhibitor. According to the superposition of MDR 769 82T and WT
HIV-1 protease structures, Pro 81 in one monomer of the MDR protease was 0.7 Å closer
to the isobutyl P1’ group of darunavir. Thr 82 was 1.6 Å further from the isobutyl P1’
group of darunavir compared to Val 82 in WT HIV-1 protease (Figure 4.1 B). The V82T
mutation changed the hydrophobicity of the binding pocket in the MDR protease.
Therefore, the hydrophilic Thr 82 pointed toward the solvent rather than the hydrophobic
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binding pocket. The 80s loop on the other monomer of the MDR protease showed an
asymmetric pattern. Both Pro 81 and Thr 82 moved away from the benzyl P1 group of
darunavir.
Table 4.3 Crystallographic statistics
Dataset
Data collection
Space group
Wavelength (Å)
Cell constants (Å)
Resolution range (Å)
Number of unique reflections
Completeness (%)
Redundancy
Mean I/σ (I)
Rmerge a
Refinement
Rwork (%)b
Rfree (%)b
Number of atoms
Ligand
Protease
Solvent
Average B factor (Å2)
Ligand
Protease
Solvent
RMSD bond length (Å)
RMSD bond angle (°)
Ramachandran plot
Allowed/generous/disallowed (%)
a

Tipranavir-MDR
769 82T co-crystal

Darunavir-MDR 769
82T co-crystal

P61
0.979
a=63.12 b=63.12
c=83.54
29.52-1.24 (1.25-1.24)
51613 (1138)
96.7 (70.9)
9.1 (2.7)
13.4 (1.2)
0.084 (0.679)

P212121
0.979
a=28.90 b=66.38
c=90.84
30.00-2.87 (2.95-2.87)
10515 (195)
98.4 (100.0)
4.4 (4.5)
11.4(3.6)
0.142 (0.486)

17.40
22.70

21.65
25.62

42
1514
351

38
1514
142

10.91
13.38
37.16
0.010
1.37

35.67
18.58
27.95
0.009
1.03

94.9/5.1/0

92.9/7.1/0

Rmerge= Σhkl Σi |Ii (hkl) - <I(hkl)>| / Σhkl Σi Ii(hkl), where Ii (hkl) is the intensity of an

observation and I(hkl) is the mean value for its unique reflection.
b

Rwork =Σhkl ||Fo|−|Fc|| / Σhkl |Fo|, where Fo and Fc are the observed and calculated structure

factor amplitudes. Rfree is calculated exactly as Rwork using a random 5% of the reflections
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omitted from refinement.

A

B

C

D

Figure 4.1 Co-crystal structures of darunavir and tipranavir with the MDR protease.
(A) The tipranavir-MDR 769 82T structure (magenta) was superimposed on the
tipranavir-WT HIV-1 protease structure (green). The I54V mutation is displayed in stick
model. The magenta and green dashed lines indicate the distance (Å) between the
inhibitor and the MDR HIV-1 protease or the WT HIV-1 protease, respectively. (B) The
conformational changes of darunavir binding to MDR 769 82T (magenta) in comparison
with the darunavir-WT HIV-1 protease complex (green). (C) The electron density of
tipranavir bound to MDR 769 82T protease is shown as an Fo –Fc OMIT map contoured
at 2σ. Two tipranavir molecules (yellow and magenta) binding in different orientation are
presented. (D) The electron density of darunavir bound to MDR 769 82T protease is
shown as an Fo –Fc OMIT map contoured at 2σ.
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4.2.3 Specific contacts were lost between darunavir or tipranavir and the MDR
HIV-1 protease
Hydrophobic interactions or hydrogen bonds were lost between the inhibitors and the
MDR protease. According to the LIGPLOT analysis, the number of residues in MDR 769
82T involved in hydrophobic interactions with darunavir or tipranavir decreased by 1~2
residues compared to that of WT HIV-1 protease. Tipranavir lost hydrophobic interactions
with Gly 49, Val 32, and Val 84 of the MDR protease but gained additional hydrophobic
interactions with Thr 82. Similarly, darunavir failed to maintain hydrophobic interactions
with Pro 81 and Ile 84 of the MDR protease but gained hydrophobic contacts with Leu 23.
The hydrogen bonding network of tipranavir was generally preserved (Figure 4.2).
Tipranavir formed hydrogen bonds with Asn 25, Asp 29, Asp 30, Gly 48, and Ile 50.
Except for the hydrogen bonds formed between the hydroxyl group of tipranavir and the
catalytic residues of the protease, all other hydrogen bonds were formed on the main
chain of the protease. Darunavir lost one hydrogen bond and altered the bonding of
another hydrogen bond in the darunavir-MDR 769 82T complex structure. The bicyclic
tetrahydrofuran P2 group of darunavir formed a pair of hydrogen bonds with Asp 29 of
WT HIV-1 protease. In the MDR protease complex, the dislocation of the P2 group of
darunavir causes it to lose one hydrogen bond with Asp 29 (Figure 4.2). The dislocation
of the sulfonamide P2’ group lost the hydrogen bond with the carboxyl group of the Asp
29 side chain, but the P2’ group formed a new hydrogen bond with the carbonyl group of
the Asp 29 main chain (Figure 4.2).
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Figure 4.2 Hydrogen bonds and hydrophobic interactions of tipranavir and
darunavir with MDR 769 82T protease. Hydrogen bonds are shown as green dashed
lines. The residues that form hydrophobic interactions with tipranavir are illustrated by
spokes. The interaction map was produced using LIGPLOT V4.5.3.

4.2.4 Tipranavir elevated the melting temperature of the protease-inhibitor complex
suggesting enhanced stability
The melting temperatures of the apo-MDR 769 82T and the MDR 769 82T in
complex with inhibitors were determined using differential scanning fluorimetry. While
eight protease-inhibitor complexes displayed a similar melting temperature to that of the
apo-MDR 769 82T (50.8 ± 0.6 °C), the tipranavir-MDR 769 82T complex shifted the
melting temperature to a higher value (62.0 ± 2.6 °C). The melting temperature of the
darunavir-protease complex was 52.6 ± 0.8 °C. The difference between the melting
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temperatures of the two complexes was 9.4 °C suggesting that tipranavir stabilized the
protease-inhibitor complex (Figure 4.3).
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Figure 4.3 The tipranavir-MDR 768 82T complex showed higher denaturation
temperature compared to the darunavir-MDR 769 82T complex. The X-axis is
temperature in Celsius degree, and the Y-axis is fluorescence change in Relative
Fluorescence Units (RFU).

4.3 Discussion
The objective of this study is to investigate how darunavir and tipranavir maintain
their inhibitory efficacy against MDR HIV-1 protease. Darunavir preserves its residual
inhibitory efficacy by forming altered hydrogen bonds while tipranavir overcomes drug
resistance by stabilizing the protease-inhibitor complex through direct interactions with
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the protease flaps.
The valine to threonine mutation at residue 82 is an isosteric switch that alters the
hydrophilic environment of the S1 and S1’ binding pocket in the protease and greatly
enhances the relative resistance to inhibitors. The valine to alanine mutation in MDR 769
is a change from a longer side chain to a shorter side chain, but the hydrophobicity of this
mutation is preserved. In both darunavir and tipranavir MDR 769 82T complex structures,
the Thr 82 residue moves away from the binding pocket towards the hydrophilic solvent
environment exhibiting greater relative resistance than the Ala 82 mutation. Darunavir,
tipranavir, and lopinavir inhibit the MDR 769 at sub-nanomolar concentration; however,
they only inhibit MDR 769 82T at approximately 3 nM. Therefore, the hydrophobicity
change in the binding pocket is more severe than contact loss in the binding pocket.
Darunavir or tipranavir binding to MDR 769 82T effectively triggers the protease flap
closure. MDR 769 82T tends to maintain the wide-open form even in the presence of
other inhibitors (105). The wide-open form of MDR 769 82T is possibly due to the fact
that M46L and I54V disrupt the rigid β-sheet of the protease flaps and therefore increase
the flexibility of the flaps.
Tipranavir, the only FDA-approved non-peptidomimetic HIV-1 protease inhibitor,
does not form the same hydrogen bonds with the flaps through a bridging water molecule
as peptidomimetic inhibitors do. Instead, tipranavir forms a hydrogen bond directly
between the carbonyl group of tipranavir and the Ile 50 residue on each MDR protease
flap. The DSF results indicate that tipranavir greatly stabilizes the inhibitor-protease
complex. Therefore, tipranavir may partially overcome drug resistance of the MDR
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protease by tightly closing the protease flaps.
Two possible drug design strategies could be considered to improve the potency of
inhibitors against MDR proteases based on the advantageous characteristics of darunavir
and tipranavir that elevate the resistance barrier to MDR protease. The first strategy is to
design chemical groups that make direct contact with the flap residues of MDR proteases
rather than mimicking substrates to interact with flaps via a bridging water molecule.
Stronger interactions between the inhibitor and protease flaps decrease the probability of
the protease-inhibitor complex dissociation. The hydrogen bonds formed directly between
the flap residue Ile50 and tipranavir reduce the protease flap flexibility caused by the
mutations, demonstrating the stability of the tipranavir-MDR protease complex.
The second strategy to improve the potency of inhibitors against MDR proteases is to
design inhibitor interactions with the main chain of the HIV-1 protease by flexible
pharmacophores. When the carboxyl group of Asp 29 is far away from the sulfonamide
P2’ group of darunavir, the P2’ group preserves a hydrogen bond with the main chain
carbonyl group of Asp 29 (Fig. 2). The main chain hydrogen bonds contribute to the
ability of darunavir to overcome drug resistance conferred by protease active site
mutations (106). Other than the P2 group, the darunavir structure is identical to
amprenavir. The flexible bicyclic tetrahydrofuran P2 group of darunavir enhances the
hydrogen bond forming propensity relative to amprenavir (27). According to the
darunavir-MDR 769 82T complex, the P2 group of darunavir adopts a different
conformation relative to the darunavir-WT HIV-1 protease complex but preserves
hydrogen bonds with the main chain of the MDR protease, suggesting that flexible drugs
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favorably form contacts in the HIV-1 protease active site cavity and maintain potency.
In summary, the inhibitor-MDR HIV-1 protease complex structures could serve as models
for drug optimization. Rather than the de novo design of new inhibitors, optimization of
existing inhibitors may have a higher chance of success against MDR variants. Minor
modifications on the protease inhibitors may restore the contacts without affecting the
bioavailability and toxicity of the molecule.

4.4 Author’s contribution
The author conducted the protein expression of the inactive MDR 768 82T, active
MDR 769 82T, and active MDR 769. The crystallization screening, crystallization setup,
structure solution, enzyme assays, DSF experiments, and analysis of results were
performed by the author. The crystal diffraction data collection and initial data processing
were conducted by Dr. Joseph S. Brunzelle from the Department of Molecular
Pharmacology and Biological Chemistry, Feinberg School of Medicine, Northwestern
University, Chicago, IL.
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CHAPTER 5 IDENTIFICATION OF A LEAD
COMPOUND TARGETING A MULTI-DRUG RESISTANT
HIV-1 PROTEASE VARIANT USING VIRTUAL
SCREENING

5.1 Introduction
The drug-resistance mutations accumulated in the HIV-1 protease during
antiretroviral therapy change the protease structure and decrease the efficacy of protease
inhibitors. Since most HIV-1 protease inhibitors were designed to mimic the substrate
cleavage intermediate, structurally diverse inhibitors are needed to maintain efficacy
against the highly flexible protease (107). The discovery of new inhibitor scaffolds is the
first step to enrich the diversity of HIV-1 protease inhibitors. The HIV-1 protease
structures greatly facilitate the discovery of new inhibitors.
Few ligand-free three-dimensional structures of HIV-1 protease have been deposited
to the Protein Data Bank. We have previously reported one such structure of an
uncomplexed MDR HIV-1 protease, MDR 769 (108). As shown in Figure 5.1, the
available ligand-free HIV-1 protease can be classified into two classes, wide-open form
and curled form (109). Considering the flexibility and dynamic movement of the protease,
the structures of the uncomplexed HIV-1 protease are as important as the ligand-bound
structures needed for successful drug design.
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Wide-open form

Curled form

Figure 5.1 The flap conformations of apo HIV-1 protease structures. The structures
include the WT HIV-1 protease NL4-3 (PDB ID: 2HB4, blue), the MDR HIV-1 protease
with mutations L24I, M46I, F53L, L63P, V77I, and V82A (PDB ID: 2HB2, magenta), the
WT HIV-1 protease isolate BRU (PDB ID: 1HHP, yellow), another WT HIV-1 protease
(PDB ID: 2PC0, green), and the MDR HIV-1 protease 769 with mutations L10I, M36V,
M46L, I54V, I62V, L63P, A71V, V82A, I84V, and L90M (PDB ID: 1TW7, orange)

Understanding the structural diversity of the target protease is essential for inhibitor
development. The plasticity of the HIV-1 protease flap region is critical in binding
substrates and inhibitors (109). The increased flap flexibility may enhance drug
cross-resistance by altering the binding pocket of protease inhibitors. Flap movement
distorts the binding cavity and therefore reduces the binding affinity to inhibitors. Direct
measurement using pulsed double electron-electron resonance (DEER) has confirmed a
larger distance between the flaps of MDR HIV-1 protease as compared to the wild-type
structure (110). Therefore, the wide-open form of HIV-1 protease can serve as a
nontraditional model to develop inhibitors targeting the open form protease. A crystal
structure has shown that the HIV-1 protease with open-flap conformation binds two
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symmetric pyrrolidine diester inhibitors (111). The range of opening and conformational
flexibility of the protease flaps demonstrate the importance of protein flexibility in
structure-based drug design. Using ensembles of protein conformations as receptors for
docking is a powerful method to increase accuracy (112, 113). Docking inhibitors based
on both the open and closed form of HIV-1 MDR protease partially represents the HIV-1
protease dynamics and improves the adaptation of the drug to the flexible movement of
the protease.

5.2 Results
The commercially-available compound libraries of TimTec Inc., Adesis Inc., and
Enamine Ltd. from the ZINC database (http://zinc.docking.org/) were initially screened
using LASSO (Ligand Activity in Surface Similarity Order) 2009 (82). Thousands of
compounds were selected to generate a smaller library for further validation using eHiTS
docking (82). The open form MDR HIV-1 protease 769 structure was used as a receptor
to identify potential inhibitor scaffolds. One compound, GR346 (Figure 5.2), showed the
best docking scores against the open form MDR 769 protease.

Figure 5.2 Chemical structure of compound GR346.
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A

B

Figure 5.3 Docking conformation of GR346 in the active site of MDR 769 HIV-1
protease. (A) GR346 was docked to the wide-open form MDR 769. (B) GR346 was
docked to the closed form MDR 769 HIV-1 protease. The blue lines represent possible
hydrogen bonds.

Figure 5.4 HIV-1 protease inhibition by the compound GR346. The MDR 769
protease is inhibited more than the wild type (NL-43) by GR346.

The binding of GR346 was examined by docking it to the closed and wide-open
forms of the MDR 769 protease using AutoDock4 (83). The docking conformation of
GR346 is shown in Figure 5.3. GR346 was originally synthesized as an NAD-dependent

75

deacetylase sirtuin-2 (SIRT2) inhibitor (IC50=56.7 µM) (114). The HIV-1 protease
inhibitory efficacy was tested using an in vitro enzyme assay (Figure 5.4). GR346
inhibited a larger percentage of MDR 769 enzyme activity at various concentrations
compared to its inhibition of the WT HIV-1 protease. At the lower compound
concentration (6.25 µM), GR346 did not inhibit the WT HIV-1 protease but it did inhibit
the MDR 769 activity by 10%. The wide-open conformation of the MDR 769 flaps
allowed the bulky compound, GR346, to easily enter the protease active site cavity. This
result suggests the possibility that larger inhibitors could fit better in the expanded active
site of MDR HIV-1 protease.

5.3 Discussion
The virtual screening experiments in this chapter have the goal of identifying a novel
scaffold as an HIV-1 protease inhibitor. GR346 with micromolar IC50 is a good lead
compound from screening. The novel protease inhibitor scaffold could be further
modified and developed to improve potency. A promising finding is the selective
inhibition of GR346 against MDR HIV-1 protease at lower concentration. The protease
inhibition assay of GR346 suggests the different ligand preference between MDR HIV-1
protease and WT HIV-1 protease. Thus, it is possible to develop MDR HIV-1 protease
specific inhibitors for AIDS patients who fail regular HIV-1 protease inhibitor treatment.
The selective binding of GR346 to the MDR HIV-1 protease may be due to the flexibility
of the MDR protease flaps. The wider inter-flap distance increases the accessibility of
bulky compounds.
Protein flexibility is an important feature in drug design. Designing drugs that make
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contacts with the protease flaps to reduce protease flexibility, and targeting the open form
protease could be options to overcome drug resistance caused by protease flap
conformation and flexibility.

5.4 Author’s contribution
The author performed the virtual screening, docking experiments, enzyme assays,
and the analysis of the data.
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CHAPTER 6 A HIGHER DESOLVATION ENERGY
REDUCES LIGAND RECOGNITION IN MULTI-DRUG
RESISTANT HIV-1 PROTEASE

6.1 Introduction
Developing novel HIV-1 protease inhibitors is a current requirement to keep pace
with the emergence of drug resistance mutations in the HIV-1 protease. Most of the
current HIV-1 protease inhibitors are designed based on substrate mimicking. In addition
to mimicking the transition state of the substrate cleavage, inhibitors designed based on
the consensus volume of substrates have been developed (115). The consensus volume of
various substrates is defined as the substrate envelope. The HIV-1 protease substrate
envelope has been determined based on the protease-substrate co-crystal structures (116).
A more realistic dynamic model of the substrate envelope has been refined using
molecular dynamics of HIV-1 protease-substrate complex structures (117). The study of
the substrate binding to various HIV-1 protease variants, especially drug-resistant variants,
facilitates the development of drugs inhibiting a broad panel of HIV-1 protease variants.
The accumulated drug-resistance mutations in the protease may alter the subsites of the
active site cavity, and therefore the inhibitor binding affinity alters accordingly. Studies
have shown that the substrate analog inhibitors contact the same set of residues of HIV-1
protease as the natural substrates do (118). Therefore, MDR HIV-1 protease variants may
also change the binding affinity to the substrates.
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Four clinical MDR HIV-1 protease variants, MDR 769, MDR 807, MDR 1385, and
MDR 3761, were isolated by Palmer et al (97), among which MDR 769 exhibited
resistance to all the tested inhibitors (119) and was successfully crystallized. The
accumulation of drug-resistance mutations also alters the structure of the MDR protease
variants. The flaps of the apo MDR 769 protease adopt a wide-open conformation (98).
Based on the available structures and known crystallization conditions, MDR 769 could
serve as a model for studying the binding patterns of MDR protease variants.
Peptidomimetic design based on the HIV-1 protease substrates is one of the popular
drug design strategies. In our study, four clinical isolates of MDR HIV-1 protease variants
were examined. The four MDR HIV-1 protease variants exhibited resistance to all US
FDA-approved HIV-1 protease inhibitors, and the substrate recognition ability is also
reduced in these proteases. In the experiment of the HIV-1 protease substrate-based
peptides competing with a fluorescent substrate, the substrate recognition of various
HIV-1 protease variants was illustrated. The results showed different recognition of the
substrates p2/NC, CA/p2 P1’F, RH/IN, and RT/RH among the five HIV-1 protease
variants. With the co-crystal structures of p2/NC and CA/p2 P1’F with MDR 769 protease,
five HIV-1 protease variants in complex with p2/NC and CA/p2 P1’F were modeled and
simulated to study the binding of substrates in the protease active site cavity. The
simulation results indicated that the MDR proteases need to overcome the higher
desolvation energy barrier to form substrate-protease complexes. The binding studies of
the heptapeptides p2/NC and CA/p2 P1’F can facilitate the identification of subsite
preference of HIV-1 protease variants and the design of drugs inhibiting a broader range

79

of MDR HIV-1 protease variants.

Table 6.1 Sequences of the HIV-1 protease variants selected
HIV-1
Sequences*
protease
PQITLWKRPL VTIKIGGQLK EALLDTGADD TVLEEMNLPG RWKPKMIGGI
NL4-3
GGFIKVRQYD QILIEICGHK AIGTVLVGPT PVNIIGRNLL TQIGCTLNF

769

PQITLWKRPI VTIKIGGQLK EALLDTGADD TVLEEVNLPG RWKPKLIGGI
GGFVKVRQYD QVPIEICGHK VIGTVLVGPT PANVIGRNLM TQIGCTLNF

807

PQITLWKRPI VTIKIGGQLK EALLDTGADD TVLEEMNLPG KWKPKIIVGI
GGFTKVRQYD NVQIEICGHK VIGAVLIGPT PANIIGRNLL TQLGCTLNF

1385

PQITLWKRPF VTIKIGGQLK EALLDTGADD TVLEEIDLPG RWKPKIIGGI
GGFIKVKQYD QIPIEICGHK VIGTVLVGPT PTNIIGRNMM TQLGCTLNF

3761

PQITLWKRPI VAIKVGGQII EALLDTGADD TVLEEMNLPG RWKPKIIGGI
GGFIKVRQYD QIPVEICGHK IITTVLVGST PVNVIGRNLM TQLGCTLNF

*The polymorphic changes are underlined. The drug-resistance mutations are in bold.

Table 6.2 Sequences of the nine HIV-1 protease cleavage sites within the HIV-1
Gag-Pol polyprotein
substrate

P3

P2

P1

P1’

P2’

P3’

P4’

MA/CA
CA/p2*
p2/NC
NC/p1
p1/p6
TF/PR
PR/RT
RT/RH
RH/IN

Gln
Arg
Thr
Gln
Gly
Phe
Leu
Glu
Lys

Asn
Val
Ile
Ala
Asn
Asn
Asn
Thr
Ile

Tyr
Leu
Met
Asn
Phe
Phe
Phe
Phe
Leu

Pro
Phe
Met
Phe
Leu
Pro
Pro
Tyr
Phe

Ile
Glu
Gln
Leu
Gln
Gln
Ile
Val
Leu

Val
Ala
Arg
Gly
Ser
Ile
Ser
Asp
Asp

Gln
Met
Gly
Lys
Arg
Thr
Pro
Gly
Gly

The cleavage site is between the P1 and P1’ residue. The CA/p2 contains an alanine to
phenylalanine mutation at P1’ position.
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6.2 Results
6.2.1 The four clinical MDR HIV-1 protease isolates are resistant to all
FDA-approved HIV-1 protease inhibitors
The drug-resistance profiles of the four clinical MDR HIV-1 protease isolates were
identified using enzyme inhibition assays. The four MDR protease variants are resistant to
all of the FDA-approved HIV-1 protease inhibitors at various levels (Figure 6.1, Table
6.3). In the table, the HIV-1 protease variant NL4-3 represents a WT HIV-1 protease.
Regarding to the inhibitory efficacy, the second generation of HIV-1 protease inhibitors
(tipranavir, darunavir, lopinavir, and atazanavir) encountered lower relative resistance.
Among the four MDR HIV-1 protease variants, MDR 807 and MDR 1385 were more
resistant to the second generation HIV-1 protease inhibitors. For the first-line HIV-1
protease inhibitors (28), higher resistance was observed to atazanavir compared to
darunavir. These results confirmed the in vitro resistance of the HIV-1 protease clinical
isolates.
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Figure 6.1 Relative resistance of the MDR HIV-1 protease variants. The y-axis is
relative resistance on a logarithmic scale while on the x-axis are the names of the
FDA-approved HIV-1 protease inhibitors.

Table 6.3 IC50 and relative resistance of FDA-approved HIV-1 protease inhibitor against HIV-1 protease variants
IC50 of HIV-1 protease inhibitors* in nM (relative resistance)
darunavir

atazanavir

lopinavir

tipranavir

nelfinavir

amprenavir

saquinavir

indinavir

ritonavir

NL4-3

0.26 (1)

0.19 (1)

0.28 (1)

0.24 (1)

1.6 (1)

0.43 (1)

0.50 (1)

0.47 (1)

0.34 (1)

MDR 769

0.74 (2.8)

2.9 (15)

0.50 (1.8)

0.65 (2.7)

110 (69)

4.8 (11)

290 (590)

120 (250)

61 (180)

MDR 807

2.0 (7.7)

7.6 (40)

1.2 (4.3)

0.63 (2.6)

210 (130)

2.9 (6.7)

850 (1700)

280 (600)

14.6 (43)

MDR 1385

3.0 (12)

4.6 (24)

2.3 (8.2)

2.8 (12)

230 (140)

3.1 (7.2)

29 (58)

140 (300)

8.0 (24)

MDR 3761

0.89 (3.4)

2.2 (12)

0.39 (1.4)

0.63 (2.6)

430 (270)

4.1 (9.5)

110 (220)

210 (450)

21 (62)
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HIV-1
Proteases

*The protease inhibitors were requested from the NIH AIDS Research and Reference Reagent Program (http://www.aidsreagent.org/).
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6.2.2 The MDR HIV-1 protease isolates exhibited different substrate binding
preference relative to the WT protease
Compared to inhibitors, the higher flexibility of substrates could match the dynamic
changes in the protease (107). The study of substrate binding facilitates the development
of peptidomimetic inhibitors. In the FRET substrate cleavage interference experiments,
the five HIV-1 protease variants show varied preferences to the nine heptapeptides. The
processing ratio in Figure 6.2 represents the ratio of the average FRET substrate
processing velocity in the presence of the heptapeptide over the average FRET substrate
processing velocity in the absence of the heptapeptide. The higher ratio indicated less
interference by the peptide on FRET substrate processing. Both the peptide and the FRET
substrate were in excess molar ratio to the HIV-1 protease, and the peptide concentration
was 40-fold higher than the FRET substrate concentration. The rate-limiting step of the
HIV-1 protease substrate, catalysis, is a chemical process rather than a physical process
(120). Therefore, interference was caused by the peptide cleavage process rather than the
peptide binding process. Once a protease-substrate complex is formed, the cleavage of
FRET substrate is slowed down. The high velocity ratios of the FRET substrate cleavage
with or without the regular peptide were due to the lower chance of forming
protease-substrate complex with the peptide. The complex formation theory was
supported by the enzyme assays using the uncleavable CA/p2 P1’F peptide. The
inhibition of the uncleavable peptide is correlated with the peptide competition results.
The IC50 values of CA/p2 P1’F pseudopeptide for NL4-3, MDR 769, MDR 807, MDR
1385, and MDR 3761 were 2.6 nM, 4.4 nM, 16.0 nM, 32.5 nM, and 55.4 nM, respectively.
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The corresponding relative resistance values were 1.7, 6.2, 13, and 21 fold, respectively.
The correlation coefficient between the FRET velocity ratios in presence of CA/p2 P1’F
and the IC50 values of CA/p2 P1’F pseudopeptide was 0.86.
The ratios of heptapeptide interference exhibited the likelihood of protease-substrate
complex formation (Figure 6.2). Compared to the WT protease, the MDR protease
variants were interfered at lower levels by the presence of regular peptides indicating the
impaired ability of the MDR HIV-1 protease to form a complex with the substrates. All
five HIV-1 protease variants had higher probability of forming complexes with the CA/p2
P1’F peptide. The presence of CA/p2 P1’F significantly slowed down the processing of
the FRET substrate. Especially, the NL4-3 and MDR 769 were completely occupied by
CA/p2 P1’F, and the fluorescent signal maintained as the base line of background signal.
The MDR 807, MDR 1385, and MDR 3761 had higher residual velocities of FRET
substrate processing with the interference of CA/p2 P1’F, suggesting the decreased
probability of complex formation. The MDR 807, MDR 1385, and MDR 3761 exhibited a
lower probability of forming complex with the substrate p2/NC compared to the WT
protease and MDR 769. All four MDR protease variants were unfavorable to form
complex with the RT/RH and RH/IN.

85

1.2

1.0

MA/CA
RH/IN
TF/PR
RT/RH
p1/p6
PR/RT
CA/p2 (P1'F)
p2/NC
NC/p1

Velocity ratio

.8

.6

.4

.2

0.0
NL4-3

MDR 769

MDR 807

MDR 1385

MDR 3761

Figure 6.2 Förster resonance energy transfer substrate processing ratio. The bar chart
represents the ratio of the average FRET substrate cleavage velocity in the presence of the
regular peptide substrate over the average FRET substrate cleavage velocity in the
absence of the regular peptide substrate. When the velocity ratio is one, the regular
peptide does not affect the FRET substrate cleavage by the protease. When the velocity
ratio is zero, the FRET substrate is completely competed out by the regular peptide.

6.2.3 The MDR protease-substrate co-crystal structures were insufficient to explain
the different substrate binding behaviors between the MDR and WT HIV-1
proteases
Based on substrate competition experiments, the substrates of interest were selected
to co-crystallize with the MDR HIV-1 protease variant. The peptides CA/p2 P1’F and
p2/NC were successfully crystallized with MDR 769 82T in P212121 space group. The
CA/p2 P1’F-MDR 769 82T and p2/NC-MDR 769 82T co-crystals diffracted to 2.10 Å
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and 2.30 Å, respectively (Table 6.4). By superposing the MDR-substrate complex
structures on corresponding WT protease-substrate complexes, the substrate backbones
were overlapped in both the MDR and WT complexes, and only minor conformational
differences were noticeable in the long flexible side chains (Figure 6.3 A, B). The P1’
group of p2/NC in complex with MDR 769 was the major conformational deviation as
compared to that of the WT complex. The results suggested that the static structures of
binding conformation are insufficient to explain the difference in substrate recognition of
HIV-1 protease variants. Dynamic simulations are required to identify the sophisticated
differences in substrate binding among HIV-1 protease variants.
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Table 6.4 Crystallographic statistics
Dataset

Data collection
Space group
Wavelength (Å)
Cell constants (Å)
Resolution range (Å)
Number of unique reflections
Completeness (%)
Redundancy
Mean I/σ (I)
Rmerge a
Refinement
Rwork (%)b
Rfree (%)b
Number of atoms
Ligand
Protease
Solvent
Average isotropic B factor (Å2)
Ligand
Protease
Solvent
RMSD bond length (Å)
RMSD bond angle (°)
Ramachandran plot
Allowed/generous/disallowed (%)
a

The MDR 769 82T in
complex of substrate
CA/p2

The MDR 769 82T in
complex of substrate
p2/NC

P212121
0.979
a=28.76 b=65.38
c=92.80
30.00-2.10(2.14-2.10)
10882 (507)
99.9 (99.0)
7.6 (6.0)
13.2 (3.4)
0.162 (0.520)

P212121
0.979
a=28.62 b=63.85
c=91.11
30.00-2.30 (2.38-2.30)
7945 (787)
98.8 (99.5)
4.0 (4.0)
10.0 (2.4)
0.114 (0.451)

17.29
23.99

20.00
27.86

60
1529
258

56
1529
137

20.28
16.83
32.62
0.008
1.06

35.32
30.46
45.32
0.009
1.26

100/0/0

99.0/1.0/0

Rmerge= Σhkl Σi |Ii (hkl) - <I(hkl)>| / Σhkl Σi Ii(hkl), where Ii (hkl) is the intensity of an

observation and I(hkl) is the mean value for its unique reflection.
b

Rwork =Σhkl ||Fo|−|Fc|| / Σhkl |Fo|, where Fo and Fc are the observed and calculated structure

factor amplitudes. Rfree is calculated exactly as Rwork using a random 5% of the reflections
omitted from refinement.
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Figure 6.3 Substrate conformation illustrating binding to the MDR protease. (A) The
CA/p2 P1’F binding to the MDR 769 82T (green) comparing to its binding to a WT
protease (grey, PDB ID: 1A8K). (B) The p2/NC binding to the MDR 769 82T (green)
comparing to its binding to a WT protease (grey, PDB ID: 1KJ7). (C) The electron
density of CA/p2 P1’F. The mesh is an Fo-Fc OMIT map at 2.0 σ. (D) The electron
density of p2/NC. The mesh is an Fo-Fc OMIT map at 2.0 σ.

6.2.4 The desolvation energy required by the MDR HIV-1 protease variants to form
protease-substrate complexes correlated with the substrate binding assay
Homology complex models of MDR 769, MDR 807, MDR 1385, MDR 3761, and
NL4-3 with p2/NC or CA/p2 were built to analyze the dynamic interactions between
substrate and protease. After 10 ns molecular dynamics simulation, the HIV-1 protease
complex models became relatively stable (Figure 6.4, 6.5), and the movement of
substrates was analyzed for the last 40 ps of simulation. The RMSD of each residue of
p2/NC or CA/p2 was plotted in Figure 6.6. The lower RMSD standard deviation suggests
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a more stable substrate-protease complex. The RMSD standard deviation values of CA/p2
binding to MDR proteases were comparable to that of CA/p2 binding to the WT HIV-1
protease. Only the Met at P4’ site was unstable in the MDR-CA/p2 complexes. This result
indicates that CA/p2 stabilizes MDR protease complexes and could serve as a template to
be further developed as a resistance overcoming peptidomimetic inhibitor. The RMSD
standard deviation values of p2/NC showed that P1 to P3 residues were stable in both the
WT HIV-1 protease and MDR proteases while the P1’ to P3’ residues were more unstable
in the MDR proteases compared to that in the WT HIV-1 protease. The P4 Gly, the tail of

RMSD value (Å)

p2/NC, underwent large movements.

Frame number

RMSD value (Å)

Figure 6.4 RMSD values of the HIV-1 protease-p2/NC complexes.

Frame number

Figure 6.5 RMSD values of the HIV-1 protease-CA/p2 complexes.
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Figure 6.6 RMSD standard deviation of substrate residues in the active site of HIV-1
protease variants.
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The interaction energy and desolvation energy between the substrates (p2/NC and
CA/p2) and HIV-1 protease variants were calculated based on the molecular
mechanics/Poisson–Boltzmann solvent-accessible surface area (MM-PBSA) method
(121). The interaction energies of the MDR 807-p2/NC and MDR 1385-p2/NC
complexes were stronger than those of other protease variant complexes. The stronger
interactions were contributed by the stronger electrostatic interaction energies. The
pattern of CA/p2 binding energies were different form that of p2/NC. The CA/p2 peptide
bound to MDR proteases were stronger resulting in stronger electrostatic interaction
energies.
The electrostatic desolvation energy is an unfavorable contribution to the binding
free energy of HIV-1 protease-substrate complexes. Compared to the electrostatic
desolvation energy, the non-polar desolvation energy was not a large component for the
binding of HIV-1 protease to p2/NC or CA/p2. The desolvation energy changes for MDR
proteases in complex with CA/p2 were higher than that for the WT complex. The p2/NC
complexes with MDR 807, MDR 1385, and MDR 3761 were calculated to have higher
desolvation energy than MDR 769 and NL4-3 complexes. Generally, MDR proteases
required to overcome higher desolvation barriers to bind substrates.
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Table 6.5 Energy analysis of the HIV-1 protease-p2/NC complex
Terms of
binding free
energy
∆Gintelec
∆GintvdW
∆Gint

HIV-1 protease
NL4-3

MDR 1385

MDR 3761

-103.7±11.9 -109.0±13.8 -136.5±22.1 -134.5±18.6

-82.5±11.9

-78.1±3.4

MDR 769

-73.4±3.8

MDR 807

-77.3±4.0

-69.4±3.5

-181.7±11.6 -182.4±13.3 -213.9±21.5 -203.9±17.6

∆Gdesolvelec
∆Gdesolvnonpolar
∆Gdesolv

-77.6±3.4
-160.1±12.0

176.0±8.9

184.2±9.6

203.9±17.8

223.2±17.7

261.6±9.1

-7.6±0.1

-7.6±0.2

-8.0±0.2

-7.4±0.2

-7.6±0.1

168.4±8.9

176.6±9.6

195.9±18

215.8±18

254.0±9.1

Table 6.6 Energy analysis of the HIV-1 protease-CA/p2 complex
Terms of
binding free
energy
∆Gintelec
∆GintvdW

HIV-1 protease
NL4-3

MDR 1385

MDR 3761

-158.7±27.6 -191.7±31.9 -193.8±25.1 -206.4±20.6

-169.3±18.5

-67.8±4.4

MDR 769

-66.6±4.4

MDR 807

-69.0±3.7

-59.3±4.4

-66.1±3.9

∆Gint

-226.5±25.9 -258.3±31.5 -262.8±24.6 -265.7±19.5

-235.5±17.5

∆Gdesolvelec

281.0±24.3

282.1±24.5

313.8±14.1

298.4±18.8

332.3±16.6

∆Gdesolvnonpolar

-7.6±0.1

-8.0±0.2

-7.5±0.2

-6.8±0.1

-7.2±0.1

∆Gdesolv

273.4±24

274.1±25

306.3±14

291.6±19

325.1±17

The interaction energies (∆Gint) between the substrate and HIV-1 proteases are the
combination of electrostatic interaction energy change (∆Gintelec) and van der Waals

93

interaction energy change (∆GintvdW). The interaction energies of the p2/NC or CA/p2
with the MDR protease variants were not weaker compared to the interaction energy with
the WT HIV-1 protease (Table 6.5, 6.6). Except for the interaction energy between p2/NC
and MDR 3761, the interaction energies with all the other MDR protease variants were
stronger than the WT protease interaction energy, which does not explain the drug
resistance and the results of substrate competition experiments. However, the energy
barrier of desolvation correlated well with velocity ratios in substrate competition
experiments. The desolvation energy (∆Gdesolv) includes the non-polar desolvation energy
(∆Gdesolvnonpolar) and the electrostatic desolvation energy (∆Gdesolvelec). The MDR proteases
require a higher desolvation energy to remove the water shell in the active site to form
complexes with the substrate (Table 6.5, 6.6). Pearson's correlation coefficient between
the velocity ratios for the p2/NC peptide (Figure 6.2) and the desolvation energies of the
p2/NC-MDR protease complexes is 0.78. Pearson's correlation coefficient for the CA/p2
dataset is 0.81.

6.3 Discussion
The study of MDR HIV-1 protease substrate preference in binding and catalysis
improves the understanding of MDR HIV-1 protease evolution as well as the effective
inhibition of the MDR protease variants. Novel drugs could be designed or optimized
according to the favorable binding of substrates to the MDR HIV-1 protease.
The identification of the substrate sub-site preference of MDR HIV-1 proteases helps
in the design of drugs that specifically inhibit MDR HIV-1 proteases. The MDR HIV-1
protease inhibitors may benefit patients who fail the regular protease inhibitor-containing
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antiretroviral therapy. According to the movement of p2/NC residues as measured by
RMSD in the protease active site (Figure 6.6), the P1’ Met is not favorable in MDR 769
and MDR 807, and P2’ Gln is not favorable in MDR 769 either. The active site blocking
behavior of CA/p2 and its interaction energy with MDR proteases suggests that the
CA/p2 peptide easily forms a strong complex with HIV-1 proteases. The tighter CA/p2
binding to the MDR protease variants as well as the reduced movement of CA/p2 in the
MDR protease active site also supports the idea that the MDR HIV-1 protease-specific
inhibitors against a panel of MDR HIV-1 protease variants could be developed using the
CA/p2 as an initial template for drug-optimization.
During the viral maturation, the processing of Gag and Gag-pol polyprotein is an
ordered process (122). The WT HIV-1 protease should maintain varying binding affinities
to the different substrates. However, in the substrate interference assays, the FRET
substrate cleavage interference pattern of the WT HIV-1 protease is not preserved in the
assays of MDR proteases. MDR proteases acquire drug-resistance by decreasing the
probability of binding to inhibitors. It is also possible for the mutations and polymorphic
substitutions to decrease the ability of MDR HIV-1 protease to bind substrates. The
change in regulated substrate site processing could be a mechanism to compensate for the
loss of viral fitness and could be a mechanism to enlarge the MDR HIV-1 variant
quasispecies populations in an infected individual. However, the short substrate peptides
used in this study may not reflect the processing order of the polyproteins cleavage sites
because the structural context and protease accessibility were not evaluated.
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The desolvation energy is an important component for substrate and inhibitor
recognition. The higher unfavorable desolvation energies of CA/p2-MDR complexes
explain the resistance to the uncleavable CA/p2 reduced peptide. In the dynamic process
of ligand binding, desolvation energy plays an important role in the ligand entry and
protease-ligand complex formation. The MDR proteases required a higher energy to
desolvate the substrate and the protease active site. The higher desolvation barrier for
MDR proteases increases the difficulty of protease-ligand complex formation. The input
structures for simulation were modeled based on the closed form MDR 769. Both the
crystal structure and direct measurement using pulsed double electron-electron resonance
(DEER) have confirmed a larger distance between the flaps of MDR 769 as compared to
the wild-type protease structure (110, 123). The wide-open conformation of the MDR
protease in the solution exposes more active site regions to solvent which may further
elevate the desolvation barrier. Since the calculation of interaction energy and desolvation
energy were performed using different methods, it is not appropriate to compare directly
between the two datasets. However, the trends of energy difference among HIV-1
protease complexes are good indicators for interpretation.
In conclusion, the difficulty in protease-ligand complex formation is increased for
MDR protease due to the high desolvation energy barrier. Drug design purely based on
the enzyme of inhibited state may not be able to reproduce the dynamic interactions
during the formation of enzyme-inhibitor complex. The results in this chapter suggest that
the desolvation of the HIV-1 protease active site is an important step in protease-ligand
complex formation as well as drug resistance. Since it is computationally costly to
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simulate the process of inhibitor-enzyme recognition, desolvation energy could serve as a
simplified parameter to be considered in drug design. The evaluation of desolvation
energy could be utilized as one standard to screen drug candidates.

6.4 Author’s contribution
The author conducted the protein expression of the inactive MDR 768 82T, active
MDR 769, active MDR 807, active MDR 1385, and active MDR 3761 HIV-1 proteases.
The crystallization screening, crystallization setups, structure solution, enzyme inhibition
assays, substrate competition assays, molecular dynamics simulations, and the analysis of
the results were performed by the author. The crystal diffraction data collection and initial
data processing were done by Dr. Joseph S. Brunzelle from the Department of Molecular
Pharmacology and Biological Chemistry, Feinberg School of Medicine, Northwestern
University, Chicago, IL.
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CHAPTER 7 STUDY OF TELAPREVIR POTENCY
AGAINST NON-GENOTYPE 1 HEPATITIS C VIRUS
PROTEASES

7.1 Introduction
Hepatitis C Virus (HCV) infection is more prevalent than HIV infection; HCV has
infected approximately 170 million people worldwide (124). About 60%~80% of the
persons infected with HCV have a chronic infection (125). To eliminate the HCV caused
public health burden, effective treatments are needed. The classic hepatitis C viral therapy
involves a combination drug cocktail; pegylated interferon-α-2a or pegylated
interferon-α-2b is paired with ribavirin in a 24-to-48 week regimen. The length of the
treatment is contingent upon the nature of viral genotype. The prospects of treatment for
hepatitis C have improved recently, particularly with the advent of such drugs as Merck &
Co., Inc.’s boceprevir (FDA approved on May 13, 2011) and Vertex Pharmaceuticals’
telaprevir (FDA approved on May 23, 2011). Both telaprevir and boceprevir are potent
HCV protease inhibitors. The HCV serine protease NS3-4A is a heterodimer comprised of
two HCV-encoded proteins, the catalytic subunit NS3 and the activation subunit NS4A.
Furthermore, the HCV NS3/4A protease employs a serine protease hydrolytic mechanism.
Zinc ions are instrumental in maintaining the structural integrity of the NS3, although
they do not play a catalytic role as they are situated at a distance from the active site.
Serine protease function is quite varied, but all enzymes employ a catalytic, active site
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serine residue that plays a central role in cleaving the substrate of choice. HCV protease
cleaves at four major junctions on the viral polyprotein precursor, which include the
NS4A/NS4B, NS4B/NS5A, NS5A/NS5B linkages, and a self-cleavage at NS3/NS4A.
The HCV serine protease NS3/4A is broadly considered to be among the most attractive
targets for anti-viral, oral drugs. Telaprevir inhibits HCV serine protease via covalent
bonding to the serine hydroxyl oxygen. Since telaprevir was developed based on
genotype 1 HCV protease, its efficacy with the other genotypes of HCV proteases is not
fully understood.
The focus of this study is to illustrate a comparison of drug resistance, among
different HCV genotypes, via molecular modeling and dynamics. Data gleaned from the
simulation can expand the present knowledge base surrounding the virus treatment by
providing new insight into yet untested interactions between these new inhibitors and
various HCV genotypes. Telaprevir was initially modeled with the HCV serine protease
NS3/4A of several different genotypes and subsequently subjected to molecular dynamics
that simulated the interaction between protease and inhibitor. The molecular dynamics
simulation allows a glimpse into the movement and interactions of the HCV
protease-telaprevir complex over time.

7.2 Results
7.2.1 HCV NS3/4A protease expression and crystallization screening
The constructs for HCV genotype 4a, 5a, and 6a proteases were designed for NS3/4A
fusion proteases. The sequences of the NS3 protease domain and the NS4A peptide for
each HCV genotypes were selected based on the closest similarity to the consensus
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sequence of a particular HCV genotype. The representative sequences for genotype 4a, 5a,
and 6a HCV NS3/4 proteases were determined and listed in Table 7.1.
The HCV NS3/4A protease from genotype 4a and 6a were made by AnaSpec, Inc.
(Fremont, CA). The expression of HCV genotype 5a protease was unsuccessful due to
low solubility. The HCV genotype 4a protease, whose concentration is higher compared
to that of HCV genotype 6a protease, was sent to Hauptman Woodward Institute (Buffalo,
NY) for a high-throughput crystal-growth screening. However, no crystallization hits
were obtained from the screening results. Moreover, no crystal grew in the grid screening
of previously published crystallization conditions of HCV genotype 1b NS3/4A protease.

Table 7.1 Representative NS3/4A fusion protease sequences for HCV genotypes 4a, 5a, and 6a
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Genotype

Strain

Accession

NS3/4 fusion protease Seq.*
MGSSHHHHHHSSGLVPRGSHMGSVVIVGRVVLSGSGSITAYAQQTRGLFSTIITSLTGRDTNENCG
EVQVLSTATQSFLGTAVNGVMWTVYHGAGSKTISGPKGPVNQMYTNVDQDLVGWPAPPGVKSLTP
CTCGASDLYLVTRHADVVPVRRRGDTRGALLSPRPISTLKGSSGGPLLCPMGHAAGLFRAAVCTRG
VAKAVDFVPVESLETTMRS
MGSSHHHHHHSSGLVPRGSHMGSVAIVGRIILSGSGSITAYAQQTRGVLGAIVLSLTGRDKNEAEG
EVQFLSTATQTFLGICINGVMWTLFHGAGSKTLAGPKGPVVQMYTNVDKDLVGWPSPPGKGSLTRC
TCGSADLYLVTRHADVIPARRRGDTRASLLSPRPISYLKGSSGGPIMCPSGHVVGVFRAAVCTRGVA
KALEFVPVENLETTMRS
MGSSHHHHHHSSGLVPRGSHMGCVVICGRITLTGSGSITAYAQQTRGLVGTIVTSLTGRDKNEVEG
EVQVVSTATQSFLATSINGVMWTVYHGAGSKTLAGPKGPVCQMYTNVDKDLVGWPSPPGARSLTP
CTCGSSDLYLVTREADVIPARRRGDNRAALLSPRPISTLKGSSGGPIMCPSGHVVGLFRAAVCTRGVA
KSLDFIPVENMETTMRS

4a

01-09

DQ418782

5a

EUH1480

Y13184

6a

6a67

DQ480520

*The N terminal sequence in bold is the His tag and thrombin cleavage site from the pET28 vector.
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7.2.2 The telaprevir derivative retained sufficient potency to inhibit genotype 4 and
6 HCV NS3/4A proteases
Enzyme IC50 of HCV proteases from genotypes 2 and 3 were measured by Dr.
Ladislau C. Kovari, during his sabbatical with Vertex Pharmaceuticals. Enzyme assays
showed the potency of telaprevir against HCV NS3/4A protease of genotype 2 was
similar to that of telaprevir against HCV genotype 1 proteases, but telaprevir exhibited
up to 10-fold less activity against genotype 3 proteases (Figure 7.1).

Figure 7.1 Genotype 1, 2, or 3 HCV protease sensitivities to telaprevir.
To further investigate the potency of telaprevir in the treatment of HCV other than
genotype 1, FRET substrate cleavage assays were performed to measure the IC50 against
genotype 4 and 6 HCV proteases. The treatment efficacy of inhibitor against HCV
genotypes from 4 and 6 can be inferred from the in vitro enzyme assays. Vertex
Pharmaceuticals kindly provided us a second generation inhibitor based on telaprevir
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named PI-1 (Figure 7.2). Inhibitor PI-1 is a specific, competitive, reversible,
peptidomimetic inhibitor of HCV NS3/4A protease, which is structurally similar to
telaprevir. PI-1 also shares the inhibition mechanism. The α-ketoamide of PI-1 forms a
reversible covalent bond with the catalytic serine in the active site. The inhibitory
efficacy of PI-1 against NS3/4A proteases of HCV genotype 1a, 4a, and 6a was tested.
The IC50 of PI-1 against genotype 1 HCV NS3/4A protease was determined as 5.54 nM.
Decreased inhibitory efficacy of PI-1 against genotype 4 and 6 HCV proteases was
observed. The IC50 values of PI-1 against genotype 4 and 6 HCV protease were 7.19 nM
and 13.9 nM, respectively (Figure 7.3). The inhibitory efficacy of PI-1 against genotype
4 HCV protease is comparable to that against genotype 1 HCV protease. The decreased
potency of PI-1 against genotype 6 HCV protease is only approximately 2-fold.

O
N
H
PI-1

O

α-ketoamides

Figure 7.2 Chemical structure of the telaprevir analog, PI-1.
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Genotype 1
IC50=5.54 nM

Genotype 4
IC50=7.19 nM
Genotype 6
IC50=13.9 nM

Figure 7.3 Inhibitor PI-1 IC50 against Genotype 1, 4, and 6 HCV proteases. The IC50
values were calculated using the SoftMax Pro Software V.5 (Molecular Devices Inc.,
Sunnyvale, CA). The IC50 values are indicated adjacent to the curves. The top panel is
the compound inhibition experiment of the WT HIV-1 protease while the bottom panel
is the compound inhibition experiment of the MDR HIV-1 protease. The curve data
points presented in this figure are average numbers of triplicate readings. The Y-axis
represents the Relative Fluorescence Units (RFU) per second. The X-axis is the
compound concentrations in nanomolar values. The empty square symbol represents the
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genotype 1 HCV protease activity curve while the solid square symbol and solid triangle
symbol represent the genotype 4 and 6 HCV protease activity curve, respectively. The
IC50 calculations were performed by fitting a four-parameter sigmoidal curve to the data
points. To calculate the IC50 value, we used the equation y = (A-D)/[1+(x/C)^B]+D,
where A and D are the Y-values corresponding to the asymptote at the lowest and
highest concentration, respectively; B is a coefficient describing the slope of the curve
(Hill coefficient); and C is the IC50 value.

7.2.3 Telaprevir exhibits less movement when it binds to HCV genotype 1 and
genotype 4a proteases
The HCV NS3/4A protease of genotypes 4a, 5a, and 6a were modeled and
simulated for 10 ns. Using the same methodology, the HCV genotype 1b NS3/4A
protease was simulated as a control. After a 10-ns simulation, the interaction of
telaprevir with the catalytic triad of HCV genotype 1 NS3/4A protease was illustrated in
Figure 7.4. The telaprevir is covalently attached to the Ser 139 hydroxyl group and
forms a hydrogen bond with His 57.
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Asp 81

Ser 139

His 57

Figure 7.4 Interaction of telaprevir with the catalytic triad of HCV genotype 1
NS3/4A protease. The catalytic triad, His 57, Asp 81, and Ser 139 are shown in stick
model. Telaprevir is represented in a green stick model. The orange cartoon model is the
NS3 protease domain and the yellow cartoon model is the cofactor NS4A.

Based on the RMSD values throughout the simulation process (Figure 7.5), the
HCV proteases of genotypes 1b and 6a had the least amount of movement from the
initial models while overall RMSD values of the HCV genotype 4a and 5a proteases
were 0.2 Å larger. The RMSD values of protease-inhibitor complexes suggested the
structural similarity between genotypes 1b and 6a proteases is greater than that between
genotype 1b protease and genotype 4a or 5a protease. Regarding the movement of
telaprevir (Figure 7.6), the RMSD values of telaprevir binding to HCV genotype 4a
proteases were larger than those of telaprevir binding to genotype 1, 5, or 6 HCV
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proteases.

Figure 7.5 RMSD values of HCV NS3/4A protease-telaprevir complexes during the
10-ns simulation.

Figure 7.6 RMSD values of telaprevir binding to various HCV NS3/4A proteases
during the 10-ns simulation.
Telapravir displayed the most relative stability when complexed with NS3/4A
protease genotypes 1 and 4 than with genotypes 5 and 6. This conclusion is supported by
considering the standard deviation of average RMSD taken from the final 200 frames of
the protease-ligand complex trajectory files (final 0.4 ns of the 10-ns simulation, Figure
7.7). A relatively lower standard deviation between plotted points (frames) of the
molecular dynamic corresponds to a relatively greater measure of protease-ligand
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complex stability.

Figure 7.7 Standard deviation of the telaprevir average RMSD during the last
400-ps of the simulation.

7.2.4 The binding between telaprevir and HCV NS3/4A genotype 1 protease
residues is superior to telaprevir complexes with the proteases of HCV genotypes 4,
5, and 6
Analysis of protease-ligand interactions is a direct way to evaluate ligand binding.
The Ligplot software (81) was used to formulate and visually represent the interactions
between the residues of a given NS3/4A protease genotype and the associated ligand,
telaprevir. The interaction maps of telaprevir with four different genotypes of HCV
proteases are represented in Figure 7.8. The genotype 1 protease-ligand complex
displayed the most favorable bonding profile, showing eight hydrogen bonds compared
with seven in both the genotype 5 and genotype 6 complexes and six in the genotype 4
complex. These data suggest that active site binding between telaprevir and the
implicated NS3/4A genotype 1 protease residues is superior to telaprevir complexes with
the remaining studied genotypes (4, 5 and 6).
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Genotype 1b

Genotype 5a

Genotype 4a

Genotype 6a

Figure 7.8 Ligplot analysis of telaprevir with the proteases from various HCV
genotypes. Hydrogen bonds appear in dashed, green line and hydrophobic interactions
are depicted with red, pronged semicircles.
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Table 7.2 Analysis results using the Protein Interfaces, Surfaces and Assemblies
server
Telaprevir complexes with

Buried area

∆Gint

Number of hydrogen

HCV NS3/4A proteases

(Å2)

(kcal/mol)

bonds with inhibitor

Genotype 1

475.9

-2.18

8

Genotype 4

492.6

-1.62

6

Genotype 5

480.2

-0.87

7

Genotype 6

475.5

-0.76

7

When genotype 1 NS3/4A protease-telaprevir complex is compared with telaprevir
binding to genotype 4, 5, and 6 proteases, the genotype 4 NS3/4A protease had fewer
hydrogen bonds with the ligand telaprevir, but more van der Waals interactions relative
to the other genotypes. The genotype 4 protease complex displayed one fewer hydrogen
bonding residue than do genotypes 1, 5 and 6 HCV proteases (Table 7.2). The genotype
4 protease complex lacked a hydrogen bond between Cys 159 and the inhibitor, whereas
genotypes 1, 5 and 6 all displayed a hydrogen bond between the Cys 159 residue and
telaprevir. The HCV protease-telaprevir interactions were further analyzed using PDBe
PISA server (126). In the PISA analysis, the covalent bond between the HCV protease
and telaprevir was manually removed. Telaprevir binding to the genotype 4 HCV
protease had the largest buried ligand area. In the Table 7.2, ∆Gint indicates the solvation
free energy gain upon complex formation, which suggested that the genotype 1 HCV
protease-telaprevir is the tightest complex among the genotype 1, 4, 5, and 6 complexes.
According to buried ligand area and ligand RMSD deviation results, the genotype 4
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HCV protease-telaprevir RMSD data suggest that telaprevir shows comparable binding
of between the 1 and 4 genotypes.
Table 7.3 Interaction energy between telaprevir and HCV proteases
Telaprevir complexes

Electrostatic

Van der Waals

Nonbonded

with HCV NS3/4A

interaction energy

interaction energy

interaction energy

proteases

(kcal/mol)

(kcal/mol)

(kcal/mol)

Genotype 1

-87.89

-55.12

-143.01

Genotype 4

-77.62

-56.88

-134.50

Genotype 5

-78.21

-55.78

-134.00

Genotype 6

-81.18

-55.69

-136.87

The interaction energy calculation of the HCV protease-telaprevir complexes
supported the results of PISA analysis. Genotype 1 HCV protease-telaprevir complex
showed the strongest total interaction energy (-143.01 kcal/mol, Table 7.3). The
Genotype 4 HCV protease-telaprevir complex was stronger in van der Waals interactions
but weaker in electrostatic interactions, which is correlated with the larger ligand buried
area and loss of one hydrogen bond in Table 7.2. In summary, based on the energy
calculations, telaprevir inhibited genotype 1 HCV protease with the best potency but
retained sufficient potency to effectively inhibit non-genotype 1 HCV proteases.

7.3 Discussion
The development of telaprevir greatly benefits the hepatitis C patients. Since
telaprevir has only been approved for the treatment of patients infected with genotype 1
HCV, more basic researches need to be conducted prior to the initiation of clinical
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studies to investigate the potency of telaprevir against non-genotype 1 HCV strains. The
first section of this study is the testing of in vitro inhibitory efficacy of the telaprevir
analog against genotype 4 and 6 HCV proteases. The second section of the study is the
determination of the structures of genotypes 4, 5, and 6 HCV proteases in complex with
telaprevir using homology modeling and molecular dynamics.
According to the enzyme assays with the telaprevir analog, PI-1, and simulation
results of the HCV protease-telaprevir complex, the binding patterns of telaprevir to
genotype 4, 5, and 6 HCV proteases are conserved. A preliminary conclusion is that
telaprevir possesses sufficient potency to treat genotype 4, 5, and 6 HCV strains.
Therefore, it is possible to expand the patient target population of telaprevir or its
derivatives to those infected with non-genotype 1 HCV variants. A weakness for the
enzyme assays is that the second generation inhibitor, a telaprevir derivative, was used
rather than original telaprevir. The potency of the telaprevir derivative in clinical tests is
unclear.
The structural study of telaprevir binding to NS3/4A proteases of different
genotypes may lead to the developing treatments for patients infected with non-genotype
1 HCV. To improve telaprevir efficacy with the other HCV genotypes, one strategy
might be to structurally modify telaprevir to restore the protease binding network, such
as the loss of hydrogen bond with the protease residue Cys 159. Another strategy is to
extend the flexible end (the P4 and P5 groups) of telaprevir to make stable contacts with
the HCV protease, which reduces the binding instability of the inhibitor.
The telaprevir binding to HCV NS3/4A protease is a two-step process. Telaprevir
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first forms a weaker non-covalent collision complex with the HCV protease, and then a
covalent bond is formed between telaprevir and the catalytic serine of the HCV protease.
In this simulation study, the HCV protease-telaprevir complexes are modeled as the
covalently attached complex. Whether telaprevir is able to successfully form the
non-covalent collision complex with non-genotype 1 HCV proteases has not been
examined. In future experiments, the ligand binding affinity of non-covalent HCV
protease-telaprevir complexes will be studied to further explore the potential of
telaprevir in the treatment of patients with non-genotype 1 HCV.

7.4 Author’s contribution
The author performed the enzyme assays and set up the molecular dynamics
simulations. The HCV protease expression experiments were carried out by the
scientists at AnaSpec, Inc. (Fremont, CA, USA). The author and his lab member, Samuel
J. Reiter, analyzed the data. Samuel J. Reiter produced the figures of the RMSD plot.
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CHAPTER 8 FUTURE DIRECTIONS

Drug discovery is still a trial-and-error testing process. Rational design and in silico
evaluation may accelerate this process. We will propose new modifications of lopinavir
and evaluate them by simulating the inhibitor-protease interactions. The promising
candidate molecules will be synthesized through collaboration with medicinal chemists.
The goal is to develop inhibitors that target with equal potency both the WT HIV-1
protease and the MDR HIV-1 protease.
The drug resistance is caused by multiple steps of dynamic interactions. Crystal
structures plus molecular dynamics are powerful tools to understand the complicated
mechanisms. In the Protein Data Bank, there are still a limited number of apo HIV-1
protease structures. Increasing the diversity of the apo HIV-1 protease structures and the
HIV-1 protease receptor structures for a given protease inhibitor will improve our
knowledge of protease flexibility upon drug binding. Furthermore, we will simulate the
movement of the protease flaps that is triggered by inhibitors, possibly linking protein
flexibility with drug resistance.
Regarding the HCV project, we will study the drug resistant of HCV protease
mutations to boceprevir, another newly approved HCV protease inhibitor. Boceprevir
inhibits the HCV protease catalytic serine through the α-ketoamide function group as
described earlier for telaprevir. During the clinical trial, several mutations that cause
boceprevir resistance have been identified. The goal is to crystallize the boceprevir
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resistant HCV NS3/4A protease mutants with or without boceprevir as starting models
for molecular dynamic simulations.
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HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS C VIRUS
PROTEASES
by
YONG WANG
May 2012
Advisor: Dr. Ladislau C. Kovari
Major: Biochemistry and Molecular Biology
Degree: Doctor of Philosophy
The antiviral drug development has improved steadily to treat the infections of
human immunodeficiency virus (HIV) and hepatitis C virus (HCV) which represent
heavy public health burdens. The viral protease plays an indispensable role in viral
maturation and therefore becomes one of the most important targets for drug design.
Nine HIV-1 protease inhibitors and two HCV protease inhibitors have been developed
and approved by the U.S. Food and Drug Administration. However, mutations in the
protease decrease reduce the efficacy the drugs. In this study, the enzyme assays indicate
that darunavir and tipranavir exhibit the most potent inhibition against the multi-drug
resistant (MDR) HIV-1 protease, which is supported by the co-crystal structures of the
MDR protease-darunavir complex and the MDR protease-tipranavir complex. The MDR
HIV-1 protease not only decreases the susceptibility to drugs but also impedes the
formation of protease-substrate complex. Molecular dynamics simulation results show
that the MDR HIV-1 protease needs to conquer a higher desolvation energy barrier to
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bind the substrate. Besides the study of drug resistance mechanisms, two drug discovery
methods have been carried out in the study. One method is the modification of a current
drug, lopinavir. The potency of the lopinavir analog against the MDR HIV-1 protease
increases. The other method is the identification of a novel HIV-1 protease inhibitor
scaffold to increase the structural diversity of inhibitors. In the HCV section, the study
focuses on an HCV NS3/4A protease inhibitor, telaprevir, which is approved for the
treatment of patients infected with the HCV genotype 1. The enzyme assays and
molecular dynamic studies suggest that telaprevir may retain sufficient potency to treat
the non-genotype 1 HCV strains.
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